| Symbol | IONS |
|---|---|
| Name | IONIS PHARMACEUTICALS INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 2855 GAZELLE COURT, CARLSBAD, CA 92010 |
| Telephone | 7609319200 |
| Fax | — |
| — | |
| Website | https://www.ionispharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000874015 |
| Description | Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Additional info from NASDAQ: |
2026-08-08 20:07
IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law
Read more
2026-08-07 03:02
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
Read more
2026-07-31 14:58
New Form S-8 - IONIS PHARMACEUTICALS INC <b>Filed:</b> 2026-07-31 <b>AccNo:</b> 0001140361-26-030454 <b>Size:</b> 228 KB
Read more
2026-07-30 14:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
Read more
2026-07-29 11:31
(30% Negative) IONIS PHARMACEUTICALS INC (IONS) Reports Q3 2026 Financial Results
Read more
2026-07-29 11:00
Ionis reports second quarter 2026 financial results and highlights progress on key programs
Read more
2026-07-23 15:30
Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSS
Read more
2026-07-23 14:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
Read more
2026-07-17 21:13
Director Reikes Peter N 🟢 acquired 3.4K shares (1 derivative) of IONIS PHARMACEUTICALS INC (IONS) Transaction Date: Jul 15, 2026 | Filing ID: 000247
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT00002187 | A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis | Na | Cytomegalovirus Retinitis | Completed | — | — | ClinicalTrials.gov |
| NCT00002156 | A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganci… | Phase2 | Cytomegalovirus Retinitis | Completed | — | — | ClinicalTrials.gov |
| NCT00002356 | The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytome… | Phase2 | Cytomegalovirus Retinitis | Completed | — | — | ClinicalTrials.gov |
| NCT00002187 | A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis | Na | Cytomegalovirus Retinitis | Completed | — | — | ClinicalTrials.gov |
| NCT00002156 | A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganci… | Phase2 | Cytomegalovirus Retinitis | Completed | — | — | ClinicalTrials.gov |
| NCT06415448 | Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema | — | Hereditary Angioedema | Available | — | — | ClinicalTrials.gov |
| NCT07487389 | Zilganersen Expanded Access Program for Individuals With Alexander Disease | — | Alexander Disease | Available | — | — | ClinicalTrials.gov |
| NCT07487389 | Zilganersen Expanded Access Program for Individuals With Alexander Disease | — | Alexander Disease | Available | — | — | ClinicalTrials.gov |
| NCT07487389 | Zilganersen Expanded Access Program for Individuals With Alexander Disease | — | Alexander Disease | Available | — | — | ClinicalTrials.gov |
| NCT06415448 | Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema | — | Hereditary Angioedema | Available | — | — | ClinicalTrials.gov |
| NCT06360237 | Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndr… | — | Familial Chylomicronemia Syndrome | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT00002356 | The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytome… | Phase2 | Cytomegalovirus Retinitis | Completed | — | — | ClinicalTrials.gov |
| NCT03400098 | ATTR Expanded Access Program (EAP) by Ionis | — | Amyloidosis, Hereditary | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT06360237 | Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndr… | — | Familial Chylomicronemia Syndrome | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT00002355 | A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalo… | Na | Cytomegalovirus Retinitis | Completed | — | — | ClinicalTrials.gov |
| NCT03400098 | ATTR Expanded Access Program (EAP) by Ionis | — | Amyloidosis, Hereditary | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT00002156 | A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganci… | Phase2 | Cytomegalovirus Retinitis | Completed | — | — | ClinicalTrials.gov |
| NCT00002355 | A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalo… | Na | Cytomegalovirus Retinitis | Completed | — | — | ClinicalTrials.gov |
| NCT00002187 | A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis | Na | Cytomegalovirus Retinitis | Completed | — | — | ClinicalTrials.gov |
| NCT06360237 | Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndr… | — | Familial Chylomicronemia Syndrome | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT00002355 | A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalo… | Na | Cytomegalovirus Retinitis | Completed | — | — | ClinicalTrials.gov |
| NCT00002356 | The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytome… | Phase2 | Cytomegalovirus Retinitis | Completed | — | — | ClinicalTrials.gov |
| NCT03400098 | ATTR Expanded Access Program (EAP) by Ionis | — | Amyloidosis, Hereditary | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT06415448 | Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema | — | Hereditary Angioedema | Available | — | — | ClinicalTrials.gov |
| NCT07727538 | A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FC… | Phase3 | Familial Chylomicronemia Syndrome | Recruiting | 2026-07-01 | 2031-08-01 | ClinicalTrials.gov |
| NCT07727538 | A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FC… | Phase3 | Familial Chylomicronemia Syndrome | Recruiting | 2026-07-01 | 2031-08-01 | ClinicalTrials.gov |
| NCT07727538 | A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FC… | Phase3 | Familial Chylomicronemia Syndrome | Recruiting | 2026-07-01 | 2031-08-01 | ClinicalTrials.gov |
| NCT07531745 | ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome | Phase1 | Dravet Syndrome | Recruiting | 2026-05-21 | 2030-12-01 | ClinicalTrials.gov |
| NCT07531745 | ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome | Phase1 | Dravet Syndrome | Recruiting | 2026-05-21 | 2030-12-01 | ClinicalTrials.gov |
| NCT07531745 | ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome | Phase1 | Dravet Syndrome | Recruiting | 2026-05-21 | 2030-12-01 | ClinicalTrials.gov |
| NCT07604974 | A Study to Assess the Safety, Tolerability and Efficacy of ION775 | Phase2 | Hypertriglyceridemia | Recruiting | 2026-05-12 | 2028-03-01 | ClinicalTrials.gov |
| NCT07604974 | A Study to Assess the Safety, Tolerability and Efficacy of ION775 | Phase2 | Hypertriglyceridemia | Recruiting | 2026-05-12 | 2028-03-01 | ClinicalTrials.gov |
| NCT07604974 | A Study to Assess the Safety, Tolerability and Efficacy of ION775 | Phase2 | Hypertriglyceridemia | Recruiting | 2026-05-12 | 2028-03-01 | ClinicalTrials.gov |
| NCT07298447 | Donidalorsen Treatment in Children With Hereditary Angioedema | Phase3 | Hereditary Angioedema (HAE) | Recruiting | 2026-04-21 | 2029-06-01 | ClinicalTrials.gov |
| NCT07298447 | Donidalorsen Treatment in Children With Hereditary Angioedema | Phase3 | Hereditary Angioedema (HAE) | Recruiting | 2026-04-21 | 2029-06-01 | ClinicalTrials.gov |
| NCT07298447 | Donidalorsen Treatment in Children With Hereditary Angioedema | Phase3 | Hereditary Angioedema (HAE) | Recruiting | 2026-04-21 | 2029-06-01 | ClinicalTrials.gov |
| NCT07287748 | A Phase I Trial of Af-001 in Patients With Differentiated Thyroid Cancer | Phase1 | DTC - Differentiated Thyroid Cancer | Recruiting | 2026-01-01 | 2028-07-31 | ClinicalTrials.gov |
| NCT07287748 | A Phase I Trial of Af-001 in Patients With Differentiated Thyroid Cancer | Phase1 | DTC - Differentiated Thyroid Cancer | Recruiting | 2026-01-01 | 2028-07-31 | ClinicalTrials.gov |
| NCT07287748 | A Phase I Trial of Af-001 in Patients With Differentiated Thyroid Cancer | Phase1 | DTC - Differentiated Thyroid Cancer | Recruiting | 2026-01-01 | 2028-07-31 | ClinicalTrials.gov |
| NCT07532824 | Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Ri… | Phase1 | Acute Myeloid Leukemia (AML) | Recruiting | 2025-11-21 | 2029-11-01 | ClinicalTrials.gov |
| NCT07532824 | Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Ri… | Phase1 | Acute Myeloid Leukemia (AML) | Recruiting | 2025-11-21 | 2029-11-01 | ClinicalTrials.gov |
| NCT07532824 | Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Ri… | Phase1 | Acute Myeloid Leukemia (AML) | Recruiting | 2025-11-21 | 2029-11-01 | ClinicalTrials.gov |
| NCT06914609 | REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome | Phase3 | Angelman Syndrome | Recruiting | 2025-06-10 | 2030-04-01 | ClinicalTrials.gov |
| NCT06914609 | REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome | Phase3 | Angelman Syndrome | Recruiting | 2025-06-10 | 2030-04-01 | ClinicalTrials.gov |
| NCT06914609 | REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome | Phase3 | Angelman Syndrome | Recruiting | 2025-06-10 | 2030-04-01 | ClinicalTrials.gov |
| NCT06809010 | grouP O wholE blooD : storagE leSion impacT And infLammation | Na | Blood Donation | Recruiting | 2025-03-12 | 2028-02-01 | ClinicalTrials.gov |
| NCT06809010 | grouP O wholE blooD : storagE leSion impacT And infLammation | Na | Blood Donation | Recruiting | 2025-03-12 | 2028-02-01 | ClinicalTrials.gov |
| NCT06809010 | grouP O wholE blooD : storagE leSion impacT And infLammation | Na | Blood Donation | Recruiting | 2025-03-12 | 2028-02-01 | ClinicalTrials.gov |
| NCT06909825 | FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-… | Phase2 | Metastatic Castration-resistant Prostate Cancer | Active_Not_Recruiting | 2025-02-26 | 2027-05-01 | ClinicalTrials.gov |
| NCT06909825 | FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-… | Phase2 | Metastatic Castration-resistant Prostate Cancer | Active_Not_Recruiting | 2025-02-26 | 2027-05-01 | ClinicalTrials.gov |
| NCT06909825 | FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-… | Phase2 | Metastatic Castration-resistant Prostate Cancer | Active_Not_Recruiting | 2025-02-26 | 2027-05-01 | ClinicalTrials.gov |
| NCT06673069 | Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) a… | Phase1 | Alzheimer Disease | Terminated | 2024-12-20 | 2025-12-03 | ClinicalTrials.gov |
| NCT06673069 | Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) a… | Phase1 | Alzheimer Disease | Terminated | 2024-12-20 | 2025-12-03 | ClinicalTrials.gov |
| NCT06673069 | Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) a… | Phase1 | Alzheimer Disease | Terminated | 2024-12-20 | 2025-12-03 | ClinicalTrials.gov |
| NCT06765876 | CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Do… | Early_Phase1 | Leukemia, Myeloid, Acute(AML) | Recruiting | 2024-10-23 | 2028-12-31 | ClinicalTrials.gov |
| NCT06765876 | CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Do… | Early_Phase1 | Leukemia, Myeloid, Acute(AML) | Recruiting | 2024-10-23 | 2028-12-31 | ClinicalTrials.gov |
| NCT06765876 | CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Do… | Early_Phase1 | Leukemia, Myeloid, Acute(AML) | Recruiting | 2024-10-23 | 2028-12-31 | ClinicalTrials.gov |
| NCT06430385 | ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pha… | Phase1 | Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome | Recruiting | 2024-10-21 | 2030-04-01 | ClinicalTrials.gov |
| NCT06430385 | ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pha… | Phase1 | Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome | Recruiting | 2024-10-21 | 2030-04-01 | ClinicalTrials.gov |
| NCT06430385 | ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pha… | Phase1 | Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome | Recruiting | 2024-10-21 | 2030-04-01 | ClinicalTrials.gov |
| NCT06150716 | Orbit Study: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodyna… | Phase1 | Pelizaeus-Merzbacher Disease | Recruiting | 2024-04-10 | 2028-06-01 | ClinicalTrials.gov |
| NCT06150716 | Orbit Study: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodyna… | Phase1 | Pelizaeus-Merzbacher Disease | Recruiting | 2024-04-10 | 2028-06-01 | ClinicalTrials.gov |
| NCT06150716 | Orbit Study: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodyna… | Phase1 | Pelizaeus-Merzbacher Disease | Recruiting | 2024-04-10 | 2028-06-01 | ClinicalTrials.gov |
| NCT06402331 | FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration… | Phase2 | Metastatic Castration-resistant Prostate Cancer | Active_Not_Recruiting | 2024-03-05 | 2031-01-23 | ClinicalTrials.gov |
| NCT06402331 | FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration… | Phase2 | Metastatic Castration-resistant Prostate Cancer | Active_Not_Recruiting | 2024-03-05 | 2031-01-23 | ClinicalTrials.gov |
| NCT06402331 | FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration… | Phase2 | Metastatic Castration-resistant Prostate Cancer | Active_Not_Recruiting | 2024-03-05 | 2031-01-23 | ClinicalTrials.gov |
| NCT06138899 | Enhancing Blood Donation at Schools and Beyond in Malawi | Na | Blood Donation | Completed | 2024-02-19 | 2026-03-10 | ClinicalTrials.gov |
| NCT06138899 | Enhancing Blood Donation at Schools and Beyond in Malawi | Na | Blood Donation | Completed | 2024-02-19 | 2026-03-10 | ClinicalTrials.gov |
| NCT06138899 | Enhancing Blood Donation at Schools and Beyond in Malawi | Na | Blood Donation | Completed | 2024-02-19 | 2026-03-10 | ClinicalTrials.gov |
| NCT06246708 | Cultural Adaptation of a Self-help App for Grieving Syrian Refugees in Switzerl… | Na | Bereavement | Completed | 2024-01-29 | 2024-06-17 | ClinicalTrials.gov |
| NCT06246708 | Cultural Adaptation of a Self-help App for Grieving Syrian Refugees in Switzerl… | Na | Bereavement | Completed | 2024-01-29 | 2024-06-17 | ClinicalTrials.gov |
| NCT06246708 | Cultural Adaptation of a Self-help App for Grieving Syrian Refugees in Switzerl… | Na | Bereavement | Completed | 2024-01-29 | 2024-06-17 | ClinicalTrials.gov |
| NCT06153966 | PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pha… | Phase1 | Prion Disease | Recruiting | 2024-01-04 | 2030-06-01 | ClinicalTrials.gov |
| NCT06153966 | PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pha… | Phase1 | Prion Disease | Recruiting | 2024-01-04 | 2030-06-01 | ClinicalTrials.gov |
| NCT06153966 | PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pha… | Phase1 | Prion Disease | Recruiting | 2024-01-04 | 2030-06-01 | ClinicalTrials.gov |
| NCT05958394 | Evaluation of Skillflix for Parents of Youth With ASD | Na | Autism Spectrum Disorder | Unknown | 2023-11-15 | 2024-03-31 | ClinicalTrials.gov |
| NCT05958394 | Evaluation of Skillflix for Parents of Youth With ASD | Na | Autism Spectrum Disorder | Unknown | 2023-11-15 | 2024-03-31 | ClinicalTrials.gov |
| NCT05958394 | Evaluation of Skillflix for Parents of Youth With ASD | Na | Autism Spectrum Disorder | Unknown | 2023-11-15 | 2024-03-31 | ClinicalTrials.gov |
| NCT06014541 | Observational Study to Characterize Biomarkers and Disease Progression in Parti… | — | Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome | Terminated | 2023-10-03 | 2025-10-07 | ClinicalTrials.gov |
| NCT06014541 | Observational Study to Characterize Biomarkers and Disease Progression in Parti… | — | Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome | Terminated | 2023-10-03 | 2025-10-07 | ClinicalTrials.gov |
| NCT06014541 | Observational Study to Characterize Biomarkers and Disease Progression in Parti… | — | Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome | Terminated | 2023-10-03 | 2025-10-07 | ClinicalTrials.gov |
| NCT06252519 | Pharmacokinetic Profile of N-Acetyl Cysteine | Na | Pharmacokinetics | Completed | 2023-09-18 | 2024-05-22 | ClinicalTrials.gov |
| NCT06252519 | Pharmacokinetic Profile of N-Acetyl Cysteine | Na | Pharmacokinetics | Completed | 2023-09-18 | 2024-05-22 | ClinicalTrials.gov |
| NCT06252519 | Pharmacokinetic Profile of N-Acetyl Cysteine | Na | Pharmacokinetics | Completed | 2023-09-18 | 2024-05-22 | ClinicalTrials.gov |
| NCT06224569 | Understanding the Effects of Daily Tea Consumption on Attention, Sleep, and Moo… | Na | The Focus of the Study is Healthy Volunteers | Completed | 2023-09-02 | 2025-05-17 | ClinicalTrials.gov |
| NCT06224569 | Understanding the Effects of Daily Tea Consumption on Attention, Sleep, and Moo… | Na | The Focus of the Study is Healthy Volunteers | Completed | 2023-09-02 | 2025-05-17 | ClinicalTrials.gov |
| NCT06224569 | Understanding the Effects of Daily Tea Consumption on Attention, Sleep, and Moo… | Na | The Focus of the Study is Healthy Volunteers | Completed | 2023-09-02 | 2025-05-17 | ClinicalTrials.gov |
| NCT06012604 | Treatment of Post-radiation Xerostomia With Allogeneic Mesenchymal Stromal Stem… | Phase1 | Xerostomia Following Radiotherapy | Unknown | 2023-09-01 | 2025-08-01 | ClinicalTrials.gov |
| NCT06012604 | Treatment of Post-radiation Xerostomia With Allogeneic Mesenchymal Stromal Stem… | Phase1 | Xerostomia Following Radiotherapy | Unknown | 2023-09-01 | 2025-08-01 | ClinicalTrials.gov |
| NCT06012604 | Treatment of Post-radiation Xerostomia With Allogeneic Mesenchymal Stromal Stem… | Phase1 | Xerostomia Following Radiotherapy | Unknown | 2023-09-01 | 2025-08-01 | ClinicalTrials.gov |
| NCT06027957 | CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Le… | Phase1 | B-Cell Non Hodgkin Lymphoma | Completed | 2023-08-02 | 2025-07-31 | ClinicalTrials.gov |
| NCT06027957 | CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Le… | Phase1 | B-Cell Non Hodgkin Lymphoma | Completed | 2023-08-02 | 2025-07-31 | ClinicalTrials.gov |
| NCT06027957 | CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Le… | Phase1 | B-Cell Non Hodgkin Lymphoma | Completed | 2023-08-02 | 2025-07-31 | ClinicalTrials.gov |
| NCT06281262 | Selected Immunological Indicators and Microbiota in Patients With Premature Bir… | — | Preterm Birth | Unknown | 2023-06-30 | 2025-03-30 | ClinicalTrials.gov |
| NCT06281262 | Selected Immunological Indicators and Microbiota in Patients With Premature Bir… | — | Preterm Birth | Unknown | 2023-06-30 | 2025-03-30 | ClinicalTrials.gov |
| NCT06281262 | Selected Immunological Indicators and Microbiota in Patients With Premature Bir… | — | Preterm Birth | Unknown | 2023-06-30 | 2025-03-30 | ClinicalTrials.gov |
| NCT05875467 | Evaluation of Prototype for Simulation for Environmental Exposure Education (SE… | Early_Phase1 | Effect of Game in Increasing Environmental Health Literacy | Completed | 2023-05-30 | 2023-07-03 | ClinicalTrials.gov |
| NCT05875467 | Evaluation of Prototype for Simulation for Environmental Exposure Education (SE… | Early_Phase1 | Effect of Game in Increasing Environmental Health Literacy | Completed | 2023-05-30 | 2023-07-03 | ClinicalTrials.gov |
| NCT05875467 | Evaluation of Prototype for Simulation for Environmental Exposure Education (SE… | Early_Phase1 | Effect of Game in Increasing Environmental Health Literacy | Completed | 2023-05-30 | 2023-07-03 | ClinicalTrials.gov |
| NCT06073587 | The CARDIO-TTRansform Scintigraphy Sub-study | — | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) | Active_Not_Recruiting | 2023-04-04 | 2026-03-01 | ClinicalTrials.gov |
| NCT06073587 | The CARDIO-TTRansform Scintigraphy Sub-study | — | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) | Active_Not_Recruiting | 2023-04-04 | 2026-03-01 | ClinicalTrials.gov |
| NCT06073587 | The CARDIO-TTRansform Scintigraphy Sub-study | — | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) | Active_Not_Recruiting | 2023-04-04 | 2026-03-01 | ClinicalTrials.gov |
| NCT05681351 | CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Par… | Phase3 | Severe Hypertriglyceridemia | Active_Not_Recruiting | 2022-12-13 | 2027-03-01 | ClinicalTrials.gov |
| NCT05681351 | CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Par… | Phase3 | Severe Hypertriglyceridemia | Active_Not_Recruiting | 2022-12-13 | 2027-03-01 | ClinicalTrials.gov |
| NCT05681351 | CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Par… | Phase3 | Severe Hypertriglyceridemia | Active_Not_Recruiting | 2022-12-13 | 2027-03-01 | ClinicalTrials.gov |
| NCT05667493 | An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Tra… | Phase3 | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | Enrolling_By_Invitation | 2022-11-30 | 2029-08-01 | ClinicalTrials.gov |
| NCT05667493 | An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Tra… | Phase3 | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | Enrolling_By_Invitation | 2022-11-30 | 2029-08-01 | ClinicalTrials.gov |
| NCT05667493 | An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Tra… | Phase3 | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | Enrolling_By_Invitation | 2022-11-30 | 2029-08-01 | ClinicalTrials.gov |
| NCT05610280 | A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia an… | Phase3 | Hypertriglyceridemia | Completed | 2022-11-21 | 2025-06-09 | ClinicalTrials.gov |
| NCT05610280 | A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia an… | Phase3 | Hypertriglyceridemia | Completed | 2022-11-21 | 2025-06-09 | ClinicalTrials.gov |
| NCT05610280 | A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia an… | Phase3 | Hypertriglyceridemia | Completed | 2022-11-21 | 2025-06-09 | ClinicalTrials.gov |
| NCT06078059 | Mechanisms of Treatment Effects Using Cultured, Allogeneic Mesenchymal Stromal … | Na | Osteoarthritis, Knee | Completed | 2022-11-01 | 2024-12-01 | ClinicalTrials.gov |
| NCT06078059 | Mechanisms of Treatment Effects Using Cultured, Allogeneic Mesenchymal Stromal … | Na | Osteoarthritis, Knee | Completed | 2022-11-01 | 2024-12-01 | ClinicalTrials.gov |
| NCT06078059 | Mechanisms of Treatment Effects Using Cultured, Allogeneic Mesenchymal Stromal … | Na | Osteoarthritis, Knee | Completed | 2022-11-01 | 2024-12-01 | ClinicalTrials.gov |
| NCT05651737 | App-based Psychosocial Intervention to Enhance Quality of Life in Arabic-speaki… | Na | Quality of Life | Completed | 2022-10-21 | 2024-03-27 | ClinicalTrials.gov |
| NCT05651737 | App-based Psychosocial Intervention to Enhance Quality of Life in Arabic-speaki… | Na | Quality of Life | Completed | 2022-10-21 | 2024-03-27 | ClinicalTrials.gov |
| NCT05651737 | App-based Psychosocial Intervention to Enhance Quality of Life in Arabic-speaki… | Na | Quality of Life | Completed | 2022-10-21 | 2024-03-27 | ClinicalTrials.gov |
| NCT05579860 | A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) Wit… | Phase1 | Healthy Participants | Completed | 2022-10-05 | 2023-05-22 | ClinicalTrials.gov |
| NCT05579860 | A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) Wit… | Phase1 | Healthy Participants | Completed | 2022-10-05 | 2023-05-22 | ClinicalTrials.gov |
| NCT05878977 | Biomarkers in Immunotherapy of Melanoma | Na | Metastatic Melanoma | Recruiting | 2022-10-05 | 2027-12-31 | ClinicalTrials.gov |
| NCT05579860 | A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) Wit… | Phase1 | Healthy Participants | Completed | 2022-10-05 | 2023-05-22 | ClinicalTrials.gov |
| NCT05878977 | Biomarkers in Immunotherapy of Melanoma | Na | Metastatic Melanoma | Recruiting | 2022-10-05 | 2027-12-31 | ClinicalTrials.gov |
| NCT05878977 | Biomarkers in Immunotherapy of Melanoma | Na | Metastatic Melanoma | Recruiting | 2022-10-05 | 2027-12-31 | ClinicalTrials.gov |
| NCT05659901 | Rocket Study: A Study to Characterize Biomarkers and Disease Progression in Par… | — | Pelizaeus-Merzbacher Disease | Recruiting | 2022-10-03 | 2029-03-01 | ClinicalTrials.gov |
| NCT05659901 | Rocket Study: A Study to Characterize Biomarkers and Disease Progression in Par… | — | Pelizaeus-Merzbacher Disease | Recruiting | 2022-10-03 | 2029-03-01 | ClinicalTrials.gov |
| NCT05659901 | Rocket Study: A Study to Characterize Biomarkers and Disease Progression in Par… | — | Pelizaeus-Merzbacher Disease | Recruiting | 2022-10-03 | 2029-03-01 | ClinicalTrials.gov |
| NCT05552326 | A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hy… | Phase3 | Severe Hypertriglyceridemia | Completed | 2022-08-31 | 2025-09-12 | ClinicalTrials.gov |
| NCT05552326 | A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hy… | Phase3 | Severe Hypertriglyceridemia | Completed | 2022-08-31 | 2025-09-12 | ClinicalTrials.gov |
| NCT05552326 | A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hy… | Phase3 | Severe Hypertriglyceridemia | Completed | 2022-08-31 | 2025-09-12 | ClinicalTrials.gov |
| NCT04165486 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Admi… | Phase1 | Multiple System Atrophy | Recruiting | 2022-07-21 | 2027-09-01 | ClinicalTrials.gov |
| NCT04165486 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Admi… | Phase1 | Multiple System Atrophy | Recruiting | 2022-07-21 | 2027-09-01 | ClinicalTrials.gov |
| NCT04165486 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Admi… | Phase1 | Multiple System Atrophy | Recruiting | 2022-07-21 | 2027-09-01 | ClinicalTrials.gov |
| NCT05392114 | A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prop… | Phase3 | Hereditary Angioedema | Active_Not_Recruiting | 2022-07-13 | 2027-03-01 | ClinicalTrials.gov |
| NCT05392114 | A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prop… | Phase3 | Hereditary Angioedema | Active_Not_Recruiting | 2022-07-13 | 2027-03-01 | ClinicalTrials.gov |
| NCT05392114 | A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prop… | Phase3 | Hereditary Angioedema | Active_Not_Recruiting | 2022-07-13 | 2027-03-01 | ClinicalTrials.gov |
| NCT05130996 | Observational Study Evaluating Safety and Performance of IDI Dental Implant Sys… | — | Dental Prosthesis | Unknown | 2022-05-09 | 2024-06-01 | ClinicalTrials.gov |
| NCT05355402 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hyper… | Phase2 | Hypertriglyceridemia | Completed | 2022-05-09 | 2023-12-21 | ClinicalTrials.gov |
| NCT05355402 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hyper… | Phase2 | Hypertriglyceridemia | Completed | 2022-05-09 | 2023-12-21 | ClinicalTrials.gov |
| NCT05130996 | Observational Study Evaluating Safety and Performance of IDI Dental Implant Sys… | — | Dental Prosthesis | Unknown | 2022-05-09 | 2024-06-01 | ClinicalTrials.gov |
| NCT05130996 | Observational Study Evaluating Safety and Performance of IDI Dental Implant Sys… | — | Dental Prosthesis | Unknown | 2022-05-09 | 2024-06-01 | ClinicalTrials.gov |
| NCT05355402 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hyper… | Phase2 | Hypertriglyceridemia | Completed | 2022-05-09 | 2023-12-21 | ClinicalTrials.gov |
| NCT05314439 | A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneou… | Phase2 | Hypertension | Completed | 2022-04-29 | 2023-02-15 | ClinicalTrials.gov |
| NCT05314439 | A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneou… | Phase2 | Hypertension | Completed | 2022-04-29 | 2023-02-15 | ClinicalTrials.gov |
| NCT05314439 | A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneou… | Phase2 | Hypertension | Completed | 2022-04-29 | 2023-02-15 | ClinicalTrials.gov |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | Phase1 | Advanced Solid Tumor | Terminated | 2022-04-20 | 2023-09-08 | ClinicalTrials.gov |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | Phase1 | Advanced Solid Tumor | Terminated | 2022-04-20 | 2023-09-08 | ClinicalTrials.gov |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | Phase1 | Advanced Solid Tumor | Terminated | 2022-04-20 | 2023-09-08 | ClinicalTrials.gov |
| NCT05185843 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adul… | Phase3 | Familial Chylomicronemia Syndrome | Active_Not_Recruiting | 2022-02-25 | 2027-06-01 | ClinicalTrials.gov |
| NCT05185843 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adul… | Phase3 | Familial Chylomicronemia Syndrome | Active_Not_Recruiting | 2022-02-25 | 2027-06-01 | ClinicalTrials.gov |
| NCT05185843 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adul… | Phase3 | Familial Chylomicronemia Syndrome | Active_Not_Recruiting | 2022-02-25 | 2027-06-01 | ClinicalTrials.gov |
| NCT05311488 | Early Detection of Neuropathy in ATTRv | — | Hereditary Amyloidosis, Transthyretin-Related | Completed | 2022-02-14 | 2026-02-14 | ClinicalTrials.gov |
| NCT05311488 | Early Detection of Neuropathy in ATTRv | — | Hereditary Amyloidosis, Transthyretin-Related | Completed | 2022-02-14 | 2026-02-14 | ClinicalTrials.gov |
| NCT05311488 | Early Detection of Neuropathy in ATTRv | — | Hereditary Amyloidosis, Transthyretin-Related | Completed | 2022-02-14 | 2026-02-14 | ClinicalTrials.gov |
| NCT05259072 | carDIo-ttranSSfOrm nucLEar Imaging Study | — | Amyloidosis | Terminated | 2022-01-19 | 2023-12-30 | ClinicalTrials.gov |
| NCT05259072 | carDIo-ttranSSfOrm nucLEar Imaging Study | — | Amyloidosis | Terminated | 2022-01-19 | 2023-12-30 | ClinicalTrials.gov |
| NCT05259072 | carDIo-ttranSSfOrm nucLEar Imaging Study | — | Amyloidosis | Terminated | 2022-01-19 | 2023-12-30 | ClinicalTrials.gov |
| NCT05071300 | A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Kn… | Phase3 | Hereditary Transthyretin-Mediated Amyloid Polyneuropathy | Active_Not_Recruiting | 2022-01-04 | 2029-08-01 | ClinicalTrials.gov |
| NCT05071300 | A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Kn… | Phase3 | Hereditary Transthyretin-Mediated Amyloid Polyneuropathy | Active_Not_Recruiting | 2022-01-04 | 2029-08-01 | ClinicalTrials.gov |
| NCT05071300 | A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Kn… | Phase3 | Hereditary Transthyretin-Mediated Amyloid Polyneuropathy | Active_Not_Recruiting | 2022-01-04 | 2029-08-01 | ClinicalTrials.gov |
| NCT05143957 | A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Pa… | Phase2 | Phlebotomy Dependent Polycythemia Vera | Completed | 2021-12-30 | 2026-06-02 | ClinicalTrials.gov |
| NCT05143957 | A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Pa… | Phase2 | Phlebotomy Dependent Polycythemia Vera | Completed | 2021-12-30 | 2026-06-02 | ClinicalTrials.gov |
| NCT05143957 | A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Pa… | Phase2 | Phlebotomy Dependent Polycythemia Vera | Completed | 2021-12-30 | 2026-06-02 | ClinicalTrials.gov |
| NCT05127226 | HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of M… | Phase1 | Angelman Syndrome | Recruiting | 2021-12-22 | 2029-03-01 | ClinicalTrials.gov |
| NCT05127226 | HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of M… | Phase1 | Angelman Syndrome | Recruiting | 2021-12-22 | 2029-03-01 | ClinicalTrials.gov |
| NCT05127226 | HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of M… | Phase1 | Angelman Syndrome | Recruiting | 2021-12-22 | 2029-03-01 | ClinicalTrials.gov |
| NCT05219500 | Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSM… | Phase2 | Metastatic Castration Resistant Prostate Cancer | Active_Not_Recruiting | 2021-12-16 | 2026-07-31 | ClinicalTrials.gov |
| NCT05219500 | Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSM… | Phase2 | Metastatic Castration Resistant Prostate Cancer | Active_Not_Recruiting | 2021-12-16 | 2026-07-31 | ClinicalTrials.gov |
| NCT05219500 | Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSM… | Phase2 | Metastatic Castration Resistant Prostate Cancer | Active_Not_Recruiting | 2021-12-16 | 2026-07-31 | ClinicalTrials.gov |
| NCT05139810 | OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 72… | Phase3 | Hereditary Angioedema | Completed | 2021-12-03 | 2023-11-09 | ClinicalTrials.gov |
| NCT05139810 | OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 72… | Phase3 | Hereditary Angioedema | Completed | 2021-12-03 | 2023-11-09 | ClinicalTrials.gov |
| NCT05139810 | OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 72… | Phase3 | Hereditary Angioedema | Completed | 2021-12-03 | 2023-11-09 | ClinicalTrials.gov |
| NCT05079126 | Study of Trans Sodium Crocetinate in Patients With Interstitial Lung Disease | Phase2 | Interstitial Lung Disease | Terminated | 2021-12-02 | 2022-05-27 | ClinicalTrials.gov |
| NCT05079126 | Study of Trans Sodium Crocetinate in Patients With Interstitial Lung Disease | Phase2 | Interstitial Lung Disease | Terminated | 2021-12-02 | 2022-05-27 | ClinicalTrials.gov |
| NCT05079126 | Study of Trans Sodium Crocetinate in Patients With Interstitial Lung Disease | Phase2 | Interstitial Lung Disease | Terminated | 2021-12-02 | 2022-05-27 | ClinicalTrials.gov |
| NCT05130450 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With… | Phase3 | Familial Chylomicronemia Syndrome | Active_Not_Recruiting | 2021-11-18 | 2028-02-01 | ClinicalTrials.gov |
| NCT05130450 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With… | Phase3 | Familial Chylomicronemia Syndrome | Active_Not_Recruiting | 2021-11-18 | 2028-02-01 | ClinicalTrials.gov |
| NCT05130450 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With… | Phase3 | Familial Chylomicronemia Syndrome | Active_Not_Recruiting | 2021-11-18 | 2028-02-01 | ClinicalTrials.gov |
| NCT05036980 | Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Trans Sodium C… | Phase1 | Healthy Volunteers With Induced Hypoxia | Completed | 2021-11-09 | 2022-04-10 | ClinicalTrials.gov |
| NCT05036980 | Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Trans Sodium C… | Phase1 | Healthy Volunteers With Induced Hypoxia | Completed | 2021-11-09 | 2022-04-10 | ClinicalTrials.gov |
| NCT05036980 | Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Trans Sodium C… | Phase1 | Healthy Volunteers With Induced Hypoxia | Completed | 2021-11-09 | 2022-04-10 | ClinicalTrials.gov |
| NCT05079919 | A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hyp… | Phase3 | Severe Hypertriglyceridemia | Completed | 2021-10-25 | 2025-07-08 | ClinicalTrials.gov |
| NCT05079919 | A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hyp… | Phase3 | Severe Hypertriglyceridemia | Completed | 2021-10-25 | 2025-07-08 | ClinicalTrials.gov |
| NCT05079919 | A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hyp… | Phase3 | Severe Hypertriglyceridemia | Completed | 2021-10-25 | 2025-07-08 | ClinicalTrials.gov |
| NCT05153954 | Quantitative ICG Fluorescence Angiography in Colorectal Surgery | — | Colorectal Cancer | Completed | 2021-08-31 | 2024-11-28 | ClinicalTrials.gov |
| NCT05637697 | Angelman Syndrome Video Assessment (ASVA) Source Material Study | — | Angelman Syndrome | Completed | 2021-08-31 | 2023-08-01 | ClinicalTrials.gov |
| NCT05637697 | Angelman Syndrome Video Assessment (ASVA) Source Material Study | — | Angelman Syndrome | Completed | 2021-08-31 | 2023-08-01 | ClinicalTrials.gov |
| NCT05153954 | Quantitative ICG Fluorescence Angiography in Colorectal Surgery | — | Colorectal Cancer | Completed | 2021-08-31 | 2024-11-28 | ClinicalTrials.gov |
| NCT05637697 | Angelman Syndrome Video Assessment (ASVA) Source Material Study | — | Angelman Syndrome | Completed | 2021-08-31 | 2023-08-01 | ClinicalTrials.gov |
| NCT05153954 | Quantitative ICG Fluorescence Angiography in Colorectal Surgery | — | Colorectal Cancer | Completed | 2021-08-31 | 2024-11-28 | ClinicalTrials.gov |
| NCT04993170 | Systematic Analysis of a Standardized Questionnaire to Detect Possible Bleeding… | — | Perioperative Hemorrhage | Completed | 2021-06-23 | 2024-06-01 | ClinicalTrials.gov |
| NCT04993170 | Systematic Analysis of a Standardized Questionnaire to Detect Possible Bleeding… | — | Perioperative Hemorrhage | Completed | 2021-06-23 | 2024-06-01 | ClinicalTrials.gov |
| NCT04993170 | Systematic Analysis of a Standardized Questionnaire to Detect Possible Bleeding… | — | Perioperative Hemorrhage | Completed | 2021-06-23 | 2024-06-01 | ClinicalTrials.gov |
| NCT04932512 | A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses … | Phase2 | Steatohepatitis, Nonalcoholic | Completed | 2021-06-17 | 2024-02-28 | ClinicalTrials.gov |
| NCT04932512 | A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses … | Phase2 | Steatohepatitis, Nonalcoholic | Completed | 2021-06-17 | 2024-02-28 | ClinicalTrials.gov |
| NCT04932512 | A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses … | Phase2 | Steatohepatitis, Nonalcoholic | Completed | 2021-06-17 | 2024-02-28 | ClinicalTrials.gov |
| NCT04768972 | FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmaco… | Phase3 | Amyotrophic Lateral Sclerosis | Active_Not_Recruiting | 2021-06-14 | 2028-03-01 | ClinicalTrials.gov |
| NCT04768972 | FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmaco… | Phase3 | Amyotrophic Lateral Sclerosis | Active_Not_Recruiting | 2021-06-14 | 2028-03-01 | ClinicalTrials.gov |
| NCT04768972 | FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmaco… | Phase3 | Amyotrophic Lateral Sclerosis | Active_Not_Recruiting | 2021-06-14 | 2028-03-01 | ClinicalTrials.gov |
| NCT04836182 | A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Par… | Phase2 | Chronic Heart Failure With Reduced Ejection Fraction | Completed | 2021-06-08 | 2023-01-11 | ClinicalTrials.gov |
| NCT04836182 | A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Par… | Phase2 | Chronic Heart Failure With Reduced Ejection Fraction | Completed | 2021-06-08 | 2023-01-11 | ClinicalTrials.gov |
| NCT04836182 | A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Par… | Phase2 | Chronic Heart Failure With Reduced Ejection Fraction | Completed | 2021-06-08 | 2023-01-11 | ClinicalTrials.gov |
| NCT05054257 | CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblasti… | Phase1 | Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia | Recruiting | 2021-06-02 | 2025-12-12 | ClinicalTrials.gov |
| NCT05054257 | CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblasti… | Phase1 | Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia | Recruiting | 2021-06-02 | 2025-12-12 | ClinicalTrials.gov |
| NCT05054257 | CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblasti… | Phase1 | Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia | Recruiting | 2021-06-02 | 2025-12-12 | ClinicalTrials.gov |
| NCT04849741 | A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients… | Phase3 | Alexander Disease | Active_Not_Recruiting | 2021-06-01 | 2029-09-01 | ClinicalTrials.gov |
| NCT04849741 | A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients… | Phase3 | Alexander Disease | Active_Not_Recruiting | 2021-06-01 | 2029-09-01 | ClinicalTrials.gov |
| NCT04849741 | A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients… | Phase3 | Alexander Disease | Active_Not_Recruiting | 2021-06-01 | 2029-09-01 | ClinicalTrials.gov |
| NCT04714320 | A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hyp… | Phase2 | Hypertension | Completed | 2021-04-28 | 2022-10-03 | ClinicalTrials.gov |
| NCT04714320 | A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hyp… | Phase2 | Hypertension | Completed | 2021-04-28 | 2022-10-03 | ClinicalTrials.gov |
| NCT04714320 | A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hyp… | Phase2 | Hypertension | Completed | 2021-04-28 | 2022-10-03 | ClinicalTrials.gov |
| NCT04296097 | Evaluation of Deep Brain Stimulation (DBS) of the Right Operculum 3 (OP3) in Pe… | Na | Severe Permanent Uni or Bilateral Non-pulsatile Tinnitus | Recruiting | 2021-04-23 | 2026-10-01 | ClinicalTrials.gov |
| NCT04296097 | Evaluation of Deep Brain Stimulation (DBS) of the Right Operculum 3 (OP3) in Pe… | Na | Severe Permanent Uni or Bilateral Non-pulsatile Tinnitus | Recruiting | 2021-04-23 | 2026-10-01 | ClinicalTrials.gov |
| NCT04296097 | Evaluation of Deep Brain Stimulation (DBS) of the Right Operculum 3 (OP3) in Pe… | Na | Severe Permanent Uni or Bilateral Non-pulsatile Tinnitus | Recruiting | 2021-04-23 | 2026-10-01 | ClinicalTrials.gov |
| NCT03897049 | Evaluation of the Trans Women Connected Mobile App for Changes in Sexual Health… | Na | HIV/AIDS | Completed | 2021-04-01 | 2022-09-07 | ClinicalTrials.gov |
| NCT03897049 | Evaluation of the Trans Women Connected Mobile App for Changes in Sexual Health… | Na | HIV/AIDS | Completed | 2021-04-01 | 2022-09-07 | ClinicalTrials.gov |
| NCT03897049 | Evaluation of the Trans Women Connected Mobile App for Changes in Sexual Health… | Na | HIV/AIDS | Completed | 2021-04-01 | 2022-09-07 | ClinicalTrials.gov |
| NCT06073574 | CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study | — | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) | Active_Not_Recruiting | 2021-03-31 | 2026-04-01 | ClinicalTrials.gov |
| NCT06073574 | CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study | — | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) | Active_Not_Recruiting | 2021-03-31 | 2026-04-01 | ClinicalTrials.gov |
| NCT06073574 | CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study | — | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) | Active_Not_Recruiting | 2021-03-31 | 2026-04-01 | ClinicalTrials.gov |
| NCT04934891 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynami… | Phase1 | Healthy Volunteers | Completed | 2021-03-24 | 2022-09-14 | ClinicalTrials.gov |
| NCT04934891 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynami… | Phase1 | Healthy Volunteers | Completed | 2021-03-24 | 2022-09-14 | ClinicalTrials.gov |
| NCT04934891 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynami… | Phase1 | Healthy Volunteers | Completed | 2021-03-24 | 2022-09-14 | ClinicalTrials.gov |
| NCT04808622 | Safety and Efficacy of Trans Sodium Crocetinate (TSC) in Enhancing Tissue Oxyge… | Phase1 | Healthy Subjects | Completed | 2021-03-17 | 2021-03-25 | ClinicalTrials.gov |
| NCT04808622 | Safety and Efficacy of Trans Sodium Crocetinate (TSC) in Enhancing Tissue Oxyge… | Phase1 | Healthy Subjects | Completed | 2021-03-17 | 2021-03-25 | ClinicalTrials.gov |
| NCT04808622 | Safety and Efficacy of Trans Sodium Crocetinate (TSC) in Enhancing Tissue Oxyge… | Phase1 | Healthy Subjects | Completed | 2021-03-17 | 2021-03-25 | ClinicalTrials.gov |
| NCT04135443 | Evaluation of 3T, a Sex-Positive HIV/STI Mobile App Intervention for Young Blac… | Na | HIV/AIDS and Infections | Completed | 2021-03-01 | 2022-11-29 | ClinicalTrials.gov |
| NCT04135443 | Evaluation of 3T, a Sex-Positive HIV/STI Mobile App Intervention for Young Blac… | Na | HIV/AIDS and Infections | Completed | 2021-03-01 | 2022-11-29 | ClinicalTrials.gov |
| NCT04135443 | Evaluation of 3T, a Sex-Positive HIV/STI Mobile App Intervention for Young Blac… | Na | HIV/AIDS and Infections | Completed | 2021-03-01 | 2022-11-29 | ClinicalTrials.gov |
| NCT04731623 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynami… | Phase1 | Healthy Volunteers | Completed | 2021-02-26 | 2021-09-11 | ClinicalTrials.gov |
| NCT04731623 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynami… | Phase1 | Healthy Volunteers | Completed | 2021-02-26 | 2021-09-11 | ClinicalTrials.gov |
| NCT04731623 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynami… | Phase1 | Healthy Volunteers | Completed | 2021-02-26 | 2021-09-11 | ClinicalTrials.gov |
| NCT04554459 | Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Ad… | Phase2 | Acute Lymphoblastic Leukemia, Adult | Terminated | 2021-02-16 | 2024-07-01 | ClinicalTrials.gov |
| NCT04554459 | Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Ad… | Phase2 | Acute Lymphoblastic Leukemia, Adult | Terminated | 2021-02-16 | 2024-07-01 | ClinicalTrials.gov |
| NCT04554459 | Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Ad… | Phase2 | Acute Lymphoblastic Leukemia, Adult | Terminated | 2021-02-16 | 2024-07-01 | ClinicalTrials.gov |
| NCT04398485 | A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple My… | Phase1 | Relapsed Multiple Myeloma | Completed | 2021-01-20 | 2024-09-30 | ClinicalTrials.gov |
| NCT04398485 | A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple My… | Phase1 | Relapsed Multiple Myeloma | Completed | 2021-01-20 | 2024-09-30 | ClinicalTrials.gov |
| NCT04398485 | A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple My… | Phase1 | Relapsed Multiple Myeloma | Completed | 2021-01-20 | 2024-09-30 | ClinicalTrials.gov |
| NCT04708483 | DCE-CT of Thoracic Tumors as an Early Biomarker for Treatment Monitoring in Com… | Na | Cancer, Lung | Unknown | 2021-01-07 | 2022-12-31 | ClinicalTrials.gov |
| NCT04708483 | DCE-CT of Thoracic Tumors as an Early Biomarker for Treatment Monitoring in Com… | Na | Cancer, Lung | Unknown | 2021-01-07 | 2022-12-31 | ClinicalTrials.gov |
| NCT04708483 | DCE-CT of Thoracic Tumors as an Early Biomarker for Treatment Monitoring in Com… | Na | Cancer, Lung | Unknown | 2021-01-07 | 2022-12-31 | ClinicalTrials.gov |
| NCT04659096 | A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors | Phase1 | Advanced Solid Tumors | Completed | 2021-01-05 | 2022-10-19 | ClinicalTrials.gov |
| NCT04659096 | A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors | Phase1 | Advanced Solid Tumors | Completed | 2021-01-05 | 2022-10-19 | ClinicalTrials.gov |
| NCT04659096 | A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors | Phase1 | Advanced Solid Tumors | Completed | 2021-01-05 | 2022-10-19 | ClinicalTrials.gov |
| NCT04522180 | A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Admin… | Phase2 | Acromegaly | Completed | 2021-01-04 | 2023-05-04 | ClinicalTrials.gov |
| NCT04522180 | A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Admin… | Phase2 | Acromegaly | Completed | 2021-01-04 | 2023-05-04 | ClinicalTrials.gov |
| NCT04522180 | A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Admin… | Phase2 | Acromegaly | Completed | 2021-01-04 | 2023-05-04 | ClinicalTrials.gov |
| NCT04441788 | A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Parti… | Phase2 | Chronic Bronchitis | Terminated | 2020-12-22 | 2021-08-09 | ClinicalTrials.gov |
| NCT04441788 | A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Parti… | Phase2 | Chronic Bronchitis | Terminated | 2020-12-22 | 2021-08-09 | ClinicalTrials.gov |
| NCT04441788 | A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Parti… | Phase2 | Chronic Bronchitis | Terminated | 2020-12-22 | 2021-08-09 | ClinicalTrials.gov |
| NCT04615208 | Screening for COVID-19 | — | Covid19 | Withdrawn | 2020-12-19 | 2021-12-30 | ClinicalTrials.gov |
| NCT04615208 | Screening for COVID-19 | — | Covid19 | Withdrawn | 2020-12-19 | 2021-12-30 | ClinicalTrials.gov |
| NCT04615208 | Screening for COVID-19 | — | Covid19 | Withdrawn | 2020-12-19 | 2021-12-30 | ClinicalTrials.gov |
| NCT04568434 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Pati… | Phase3 | Familial Chylomicronemia Syndrome | Completed | 2020-11-18 | 2023-10-17 | ClinicalTrials.gov |
| NCT04568434 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Pati… | Phase3 | Familial Chylomicronemia Syndrome | Completed | 2020-11-18 | 2023-10-17 | ClinicalTrials.gov |
| NCT04568434 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Pati… | Phase3 | Familial Chylomicronemia Syndrome | Completed | 2020-11-18 | 2023-10-17 | ClinicalTrials.gov |
| NCT04549922 | Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19 | Phase2 | Covid19 | Completed | 2020-10-19 | 2021-12-09 | ClinicalTrials.gov |
| NCT04549922 | Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19 | Phase2 | Covid19 | Completed | 2020-10-19 | 2021-12-09 | ClinicalTrials.gov |
| NCT04549922 | Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19 | Phase2 | Covid19 | Completed | 2020-10-19 | 2021-12-09 | ClinicalTrials.gov |
| NCT04059406 | Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pha… | Phase2 | Beta Thalassemia Intermedia | Terminated | 2020-09-24 | 2023-03-28 | ClinicalTrials.gov |
| NCT04059406 | Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pha… | Phase2 | Beta Thalassemia Intermedia | Terminated | 2020-09-24 | 2023-03-28 | ClinicalTrials.gov |
| NCT04059406 | Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pha… | Phase2 | Beta Thalassemia Intermedia | Terminated | 2020-09-24 | 2023-03-28 | ClinicalTrials.gov |
| NCT04573322 | Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) … | Phase1 | SARS-CoV-2 (Covid19) | Completed | 2020-09-10 | 2021-04-29 | ClinicalTrials.gov |
| NCT04573322 | Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) … | Phase1 | SARS-CoV-2 (Covid19) | Completed | 2020-09-10 | 2021-04-29 | ClinicalTrials.gov |
| NCT04573322 | Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) … | Phase1 | SARS-CoV-2 (Covid19) | Completed | 2020-09-10 | 2021-04-29 | ClinicalTrials.gov |
| NCT05200754 | Trial With or Without Infusion of SARS-CoV-2 Antibody Containing Plasma in High… | Phase2 | SARS-CoV-2 Infection | Unknown | 2020-09-03 | 2022-06-01 | ClinicalTrials.gov |
| NCT05200754 | Trial With or Without Infusion of SARS-CoV-2 Antibody Containing Plasma in High… | Phase2 | SARS-CoV-2 Infection | Unknown | 2020-09-03 | 2022-06-01 | ClinicalTrials.gov |
| NCT05200754 | Trial With or Without Infusion of SARS-CoV-2 Antibody Containing Plasma in High… | Phase2 | SARS-CoV-2 Infection | Unknown | 2020-09-03 | 2022-06-01 | ClinicalTrials.gov |
| NCT04516954 | Convalescent Plasma for COVID-19 Patients | Early_Phase1 | COVID 19 | Completed | 2020-08-01 | 2021-04-30 | ClinicalTrials.gov |
| NCT04516954 | Convalescent Plasma for COVID-19 Patients | Early_Phase1 | COVID 19 | Completed | 2020-08-01 | 2021-04-30 | ClinicalTrials.gov |
| NCT04516954 | Convalescent Plasma for COVID-19 Patients | Early_Phase1 | COVID 19 | Completed | 2020-08-01 | 2021-04-30 | ClinicalTrials.gov |
| NCT04542941 | Assessment of Safety and Efficacy of CCP | Na | Covid19 | Completed | 2020-06-16 | 2020-12-31 | ClinicalTrials.gov |
| NCT04542941 | Assessment of Safety and Efficacy of CCP | Na | Covid19 | Completed | 2020-06-16 | 2020-12-31 | ClinicalTrials.gov |
| NCT04542941 | Assessment of Safety and Efficacy of CCP | Na | Covid19 | Completed | 2020-06-16 | 2020-12-31 | ClinicalTrials.gov |
| NCT04626661 | Mitochondrial Oxygen Measurement Variability in Critically Ill Patients (INOX V… | — | Mitochondrial Oxygenation Measurement | Completed | 2020-06-15 | 2023-05-17 | ClinicalTrials.gov |
| NCT04626661 | Mitochondrial Oxygen Measurement Variability in Critically Ill Patients (INOX V… | — | Mitochondrial Oxygenation Measurement | Completed | 2020-06-15 | 2023-05-17 | ClinicalTrials.gov |
| NCT04626661 | Mitochondrial Oxygen Measurement Variability in Critically Ill Patients (INOX V… | — | Mitochondrial Oxygenation Measurement | Completed | 2020-06-15 | 2023-05-17 | ClinicalTrials.gov |
| NCT04288128 | Integrated Functional Evaluation of the Cerebellum | — | Spinocerebellar Ataxia Type 2 | Completed | 2020-05-28 | 2022-06-01 | ClinicalTrials.gov |
| NCT04288128 | Integrated Functional Evaluation of the Cerebellum | — | Spinocerebellar Ataxia Type 2 | Completed | 2020-05-28 | 2022-06-01 | ClinicalTrials.gov |
| NCT04288128 | Integrated Functional Evaluation of the Cerebellum | — | Spinocerebellar Ataxia Type 2 | Completed | 2020-05-28 | 2022-06-01 | ClinicalTrials.gov |
| NCT04356482 | CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19 | Phase1 | COVID-19 | Unknown | 2020-05-20 | 2020-12-01 | ClinicalTrials.gov |
| NCT04356482 | CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19 | Phase1 | COVID-19 | Unknown | 2020-05-20 | 2020-12-01 | ClinicalTrials.gov |
| NCT04356482 | CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19 | Phase1 | COVID-19 | Unknown | 2020-05-20 | 2020-12-01 | ClinicalTrials.gov |
| NCT04302064 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynam… | Phase1 | Healthy Participants | Completed | 2020-04-23 | 2020-09-10 | ClinicalTrials.gov |
| NCT04302064 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynam… | Phase1 | Healthy Participants | Completed | 2020-04-23 | 2020-09-10 | ClinicalTrials.gov |
| NCT04302064 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynam… | Phase1 | Healthy Participants | Completed | 2020-04-23 | 2020-09-10 | ClinicalTrials.gov |
| NCT06831799 | ERN-EuroBloodNet Registry on Patients With Rare Red Blood Cell Defects and COVI… | — | Hemoglobinopathies | Completed | 2020-04-15 | 2023-12-31 | ClinicalTrials.gov |
| NCT06831799 | ERN-EuroBloodNet Registry on Patients With Rare Red Blood Cell Defects and COVI… | — | Hemoglobinopathies | Completed | 2020-04-15 | 2023-12-31 | ClinicalTrials.gov |
| NCT06831799 | ERN-EuroBloodNet Registry on Patients With Rare Red Blood Cell Defects and COVI… | — | Hemoglobinopathies | Completed | 2020-04-15 | 2023-12-31 | ClinicalTrials.gov |
| NCT04307381 | An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Heredit… | Phase2 | Hereditary Angioedema | Completed | 2020-03-31 | 2025-01-24 | ClinicalTrials.gov |
| NCT04307381 | An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Heredit… | Phase2 | Hereditary Angioedema | Completed | 2020-03-31 | 2025-01-24 | ClinicalTrials.gov |
| NCT04307381 | An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Heredit… | Phase2 | Hereditary Angioedema | Completed | 2020-03-31 | 2025-01-24 | ClinicalTrials.gov |
| NCT04136171 | CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (… | Phase3 | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | Active_Not_Recruiting | 2020-03-13 | 2026-08-01 | ClinicalTrials.gov |
| NCT04136171 | CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (… | Phase3 | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | Active_Not_Recruiting | 2020-03-13 | 2026-08-01 | ClinicalTrials.gov |
| NCT04136171 | CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (… | Phase3 | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | Active_Not_Recruiting | 2020-03-13 | 2026-08-01 | ClinicalTrials.gov |
| NCT04199403 | Assessment of Complication Risk Factors in a French National Cohort of Asplenic… | — | Asplenia | Recruiting | 2020-01-09 | 2040-01-01 | ClinicalTrials.gov |
| NCT04199403 | Assessment of Complication Risk Factors in a French National Cohort of Asplenic… | — | Asplenia | Recruiting | 2020-01-09 | 2040-01-01 | ClinicalTrials.gov |
| NCT04199403 | Assessment of Complication Risk Factors in a French National Cohort of Asplenic… | — | Asplenia | Recruiting | 2020-01-09 | 2040-01-01 | ClinicalTrials.gov |
| NCT04030598 | A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PK… | Phase2 | Hereditary Angioedema | Completed | 2020-01-07 | 2021-03-01 | ClinicalTrials.gov |
| NCT04030598 | A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PK… | Phase2 | Hereditary Angioedema | Completed | 2020-01-07 | 2021-03-01 | ClinicalTrials.gov |
| NCT04030598 | A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PK… | Phase2 | Hereditary Angioedema | Completed | 2020-01-07 | 2021-03-01 | ClinicalTrials.gov |
| NCT04529382 | Neurodevelopmental Outcome After Fetal Neonatal AlloImmune Thrombocytopenia | — | Fetal and Neonatal Alloimmune Thrombocytopenia | Unknown | 2019-12-17 | 2021-12-17 | ClinicalTrials.gov |
| NCT04529382 | Neurodevelopmental Outcome After Fetal Neonatal AlloImmune Thrombocytopenia | — | Fetal and Neonatal Alloimmune Thrombocytopenia | Unknown | 2019-12-17 | 2021-12-17 | ClinicalTrials.gov |
| NCT04529382 | Neurodevelopmental Outcome After Fetal Neonatal AlloImmune Thrombocytopenia | — | Fetal and Neonatal Alloimmune Thrombocytopenia | Unknown | 2019-12-17 | 2021-12-17 | ClinicalTrials.gov |
| NCT04136184 | NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (F… | Phase3 | Hereditary Transthyretin-Mediated Amyloid Polyneuropathy | Completed | 2019-12-11 | 2023-07-12 | ClinicalTrials.gov |
| NCT04136184 | NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (F… | Phase3 | Hereditary Transthyretin-Mediated Amyloid Polyneuropathy | Completed | 2019-12-11 | 2023-07-12 | ClinicalTrials.gov |
| NCT04136184 | NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (F… | Phase3 | Hereditary Transthyretin-Mediated Amyloid Polyneuropathy | Completed | 2019-12-11 | 2023-07-12 | ClinicalTrials.gov |
| NCT04014335 | A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense … | Phase2 | Primary IgA Nephropathy | Completed | 2019-12-04 | 2024-04-11 | ClinicalTrials.gov |
| NCT04014335 | A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense … | Phase2 | Primary IgA Nephropathy | Completed | 2019-12-04 | 2024-04-11 | ClinicalTrials.gov |
| NCT04014335 | A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense … | Phase2 | Primary IgA Nephropathy | Completed | 2019-12-04 | 2024-04-11 | ClinicalTrials.gov |
| NCT04083222 | A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx | Phase2 | Hypertension | Completed | 2019-11-13 | 2020-07-20 | ClinicalTrials.gov |
| NCT04083222 | A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx | Phase2 | Hypertension | Completed | 2019-11-13 | 2020-07-20 | ClinicalTrials.gov |
| NCT04083222 | A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx | Phase2 | Hypertension | Completed | 2019-11-13 | 2020-07-20 | ClinicalTrials.gov |
| NCT03984058 | Recruitment Strategies Comparing Different Strategies in Sleep Apnea and Predia… | Na | Sleep Disorder | Completed | 2019-10-01 | 2021-05-17 | ClinicalTrials.gov |
| NCT03984058 | Recruitment Strategies Comparing Different Strategies in Sleep Apnea and Predia… | Na | Sleep Disorder | Completed | 2019-10-01 | 2021-05-17 | ClinicalTrials.gov |
| NCT03984058 | Recruitment Strategies Comparing Different Strategies in Sleep Apnea and Predia… | Na | Sleep Disorder | Completed | 2019-10-01 | 2021-05-17 | ClinicalTrials.gov |
| NCT03763929 | Efficacy and Safety of Trans Sodium Crocetinate (TSC) for Treatment of Suspecte… | Phase2 | Stroke, Acute | Terminated | 2019-08-22 | 2020-10-19 | ClinicalTrials.gov |
| NCT03763929 | Efficacy and Safety of Trans Sodium Crocetinate (TSC) for Treatment of Suspecte… | Phase2 | Stroke, Acute | Terminated | 2019-08-22 | 2020-10-19 | ClinicalTrials.gov |
| NCT03763929 | Efficacy and Safety of Trans Sodium Crocetinate (TSC) for Treatment of Suspecte… | Phase2 | Stroke, Acute | Terminated | 2019-08-22 | 2020-10-19 | ClinicalTrials.gov |
| NCT03976349 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 i… | Phase1 | Parkinson's Disease | Completed | 2019-08-12 | 2024-08-12 | ClinicalTrials.gov |
| NCT03976349 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 i… | Phase1 | Parkinson's Disease | Completed | 2019-08-12 | 2024-08-12 | ClinicalTrials.gov |
| NCT03976349 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 i… | Phase1 | Parkinson's Disease | Completed | 2019-08-12 | 2024-08-12 | ClinicalTrials.gov |
| NCT03967249 | Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly B… | Phase2 | Acromegaly | Completed | 2019-07-25 | 2022-07-07 | ClinicalTrials.gov |
| NCT03967249 | Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly B… | Phase2 | Acromegaly | Completed | 2019-07-25 | 2022-07-07 | ClinicalTrials.gov |
| NCT03967249 | Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly B… | Phase2 | Acromegaly | Completed | 2019-07-25 | 2022-07-07 | ClinicalTrials.gov |
| NCT04096391 | Post-market, Randomized, Controlled, Prospective Study Evaluating Intrathecal P… | Na | Chronic Nonmalignant Pain | Completed | 2019-06-05 | 2022-04-11 | ClinicalTrials.gov |
| NCT04096391 | Post-market, Randomized, Controlled, Prospective Study Evaluating Intrathecal P… | Na | Chronic Nonmalignant Pain | Completed | 2019-06-05 | 2022-04-11 | ClinicalTrials.gov |
| NCT04096391 | Post-market, Randomized, Controlled, Prospective Study Evaluating Intrathecal P… | Na | Chronic Nonmalignant Pain | Completed | 2019-06-05 | 2022-04-11 | ClinicalTrials.gov |
| NCT03812653 | Sleep for Stroke Management and Recovery Trial | Na | Ischemic Stroke | Active_Not_Recruiting | 2019-05-09 | 2026-11-01 | ClinicalTrials.gov |
| NCT04554485 | Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphobla… | Phase2 | Lymphoblastic Leukemia, Acute, Adult | Completed | 2019-05-09 | 2024-02-29 | ClinicalTrials.gov |
| NCT04554485 | Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphobla… | Phase2 | Lymphoblastic Leukemia, Acute, Adult | Completed | 2019-05-09 | 2024-02-29 | ClinicalTrials.gov |
| NCT03812653 | Sleep for Stroke Management and Recovery Trial | Na | Ischemic Stroke | Active_Not_Recruiting | 2019-05-09 | 2026-11-01 | ClinicalTrials.gov |
| NCT04554485 | Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphobla… | Phase2 | Lymphoblastic Leukemia, Acute, Adult | Completed | 2019-05-09 | 2024-02-29 | ClinicalTrials.gov |
| NCT03812653 | Sleep for Stroke Management and Recovery Trial | Na | Ischemic Stroke | Active_Not_Recruiting | 2019-05-09 | 2026-11-01 | ClinicalTrials.gov |
| NCT03815825 | GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-… | Phase2 | Macular Degeneration | Completed | 2019-03-04 | 2024-06-12 | ClinicalTrials.gov |
| NCT03815825 | GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-… | Phase2 | Macular Degeneration | Completed | 2019-03-04 | 2024-06-12 | ClinicalTrials.gov |
| NCT03815825 | GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-… | Phase2 | Macular Degeneration | Completed | 2019-03-04 | 2024-06-12 | ClinicalTrials.gov |
| NCT03842722 | Insufficient Oxygenation in Septic Patients | — | Sepsis | Completed | 2019-02-13 | 2023-09-28 | ClinicalTrials.gov |
| NCT03842722 | Insufficient Oxygenation in Septic Patients | — | Sepsis | Completed | 2019-02-13 | 2023-09-28 | ClinicalTrials.gov |
| NCT03842722 | Insufficient Oxygenation in Septic Patients | — | Sepsis | Completed | 2019-02-13 | 2023-09-28 | ClinicalTrials.gov |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | Phase1 | Advanced Solid Tumours | Terminated | 2019-01-17 | 2025-12-03 | ClinicalTrials.gov |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | Phase1 | Advanced Solid Tumours | Terminated | 2019-01-17 | 2025-12-03 | ClinicalTrials.gov |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | Phase1 | Advanced Solid Tumours | Terminated | 2019-01-17 | 2025-12-03 | ClinicalTrials.gov |
| NCT03876522 | Natural History and Functional Status Study of Patients With Lafora Disease | — | Lafora Disease | Completed | 2019-01-09 | 2022-04-01 | ClinicalTrials.gov |
| NCT03876522 | Natural History and Functional Status Study of Patients With Lafora Disease | — | Lafora Disease | Completed | 2019-01-09 | 2022-04-01 | ClinicalTrials.gov |
| NCT03876522 | Natural History and Functional Status Study of Patients With Lafora Disease | — | Lafora Disease | Completed | 2019-01-09 | 2022-04-01 | ClinicalTrials.gov |
| NCT04227236 | Interventions to Improve Reproductive Health Among Adolescents | Na | Teacher Training | Completed | 2019-01-07 | 2019-04-17 | ClinicalTrials.gov |
| NCT04227236 | Interventions to Improve Reproductive Health Among Adolescents | Na | Teacher Training | Completed | 2019-01-07 | 2019-04-17 | ClinicalTrials.gov |
| NCT04227236 | Interventions to Improve Reproductive Health Among Adolescents | Na | Teacher Training | Completed | 2019-01-07 | 2019-04-17 | ClinicalTrials.gov |
| NCT03714776 | A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an An… | Phase2 | Mild Hypertension | Completed | 2019-01-03 | 2019-11-13 | ClinicalTrials.gov |
| NCT03714776 | A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an An… | Phase2 | Mild Hypertension | Completed | 2019-01-03 | 2019-11-13 | ClinicalTrials.gov |
| NCT03714776 | A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an An… | Phase2 | Mild Hypertension | Completed | 2019-01-03 | 2019-11-13 | ClinicalTrials.gov |
| NCT03728634 | Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharma… | Phase1 | Healthy Volunteers | Completed | 2018-12-21 | 2020-02-20 | ClinicalTrials.gov |
| NCT03728634 | Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharma… | Phase1 | Healthy Volunteers | Completed | 2018-12-21 | 2020-02-20 | ClinicalTrials.gov |
| NCT03728634 | Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharma… | Phase1 | Healthy Volunteers | Completed | 2018-12-21 | 2020-02-20 | ClinicalTrials.gov |
| NCT03647228 | A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pha… | Phase1 | Healthy Subjects | Completed | 2018-12-13 | 2020-10-13 | ClinicalTrials.gov |
| NCT03647228 | A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pha… | Phase1 | Healthy Subjects | Completed | 2018-12-13 | 2020-10-13 | ClinicalTrials.gov |
| NCT03647228 | A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pha… | Phase1 | Healthy Subjects | Completed | 2018-12-13 | 2020-10-13 | ClinicalTrials.gov |
| NCT03505086 | Bleeding In Thrombocytopenia Explained | — | Hematologic Neoplasms | Recruiting | 2018-12-04 | 2026-06-01 | ClinicalTrials.gov |
| NCT03505086 | Bleeding In Thrombocytopenia Explained | — | Hematologic Neoplasms | Recruiting | 2018-12-04 | 2026-06-01 | ClinicalTrials.gov |
| NCT03505086 | Bleeding In Thrombocytopenia Explained | — | Hematologic Neoplasms | Recruiting | 2018-12-04 | 2026-06-01 | ClinicalTrials.gov |
| NCT05337878 | A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics … | Phase1 | Healthy Participants | Completed | 2018-10-15 | 2019-12-18 | ClinicalTrials.gov |
| NCT05337878 | A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics … | Phase1 | Healthy Participants | Completed | 2018-10-15 | 2019-12-18 | ClinicalTrials.gov |
| NCT05337878 | A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics … | Phase1 | Healthy Participants | Completed | 2018-10-15 | 2019-12-18 | ClinicalTrials.gov |
| NCT06167928 | Developing Allogeneic Musculoskeletal Therapies | — | Osteoarthritis | Recruiting | 2018-10-08 | 2037-09-01 | ClinicalTrials.gov |
| NCT06167928 | Developing Allogeneic Musculoskeletal Therapies | — | Osteoarthritis | Recruiting | 2018-10-08 | 2037-09-01 | ClinicalTrials.gov |
| NCT06167928 | Developing Allogeneic Musculoskeletal Therapies | — | Osteoarthritis | Recruiting | 2018-10-08 | 2037-09-01 | ClinicalTrials.gov |
| NCT03548415 | Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acrome… | Phase2 | Acromegaly | Completed | 2018-09-13 | 2021-04-02 | ClinicalTrials.gov |
| NCT03548415 | Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acrome… | Phase2 | Acromegaly | Completed | 2018-09-13 | 2021-04-02 | ClinicalTrials.gov |
| NCT03548415 | Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acrome… | Phase2 | Acromegaly | Completed | 2018-09-13 | 2021-04-02 | ClinicalTrials.gov |
| NCT03551964 | Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction | Phase4 | Acute Myocardial Infarction | Completed | 2018-08-01 | 2025-04-01 | ClinicalTrials.gov |
| NCT03551964 | Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction | Phase4 | Acute Myocardial Infarction | Completed | 2018-08-01 | 2025-04-01 | ClinicalTrials.gov |
| NCT03551964 | Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction | Phase4 | Acute Myocardial Infarction | Completed | 2018-08-01 | 2025-04-01 | ClinicalTrials.gov |
| NCT03582462 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynam… | Phase1 | Healthy Participants | Completed | 2018-07-09 | 2019-04-26 | ClinicalTrials.gov |
| NCT03582462 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynam… | Phase1 | Healthy Participants | Completed | 2018-07-09 | 2019-04-26 | ClinicalTrials.gov |
| NCT03582462 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynam… | Phase1 | Healthy Participants | Completed | 2018-07-09 | 2019-04-26 | ClinicalTrials.gov |
| NCT03514420 | Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial … | Phase2 | Familial Partial Lipodystrophy | Completed | 2018-06-15 | 2019-08-21 | ClinicalTrials.gov |
| NCT03514420 | Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial … | Phase2 | Familial Partial Lipodystrophy | Completed | 2018-06-15 | 2019-08-21 | ClinicalTrials.gov |
| NCT03514420 | Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial … | Phase2 | Familial Partial Lipodystrophy | Completed | 2018-06-15 | 2019-08-21 | ClinicalTrials.gov |
| NCT03601221 | Seroprevalence Hepatitis E Infection in Healthy Blood Donors | — | Hepatitis E | Completed | 2018-05-29 | 2019-12-31 | ClinicalTrials.gov |
| NCT03601221 | Seroprevalence Hepatitis E Infection in Healthy Blood Donors | — | Hepatitis E | Completed | 2018-05-29 | 2019-12-31 | ClinicalTrials.gov |
| NCT03601221 | Seroprevalence Hepatitis E Infection in Healthy Blood Donors | — | Hepatitis E | Completed | 2018-05-29 | 2019-12-31 | ClinicalTrials.gov |
| NCT03455777 | Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial H… | Phase2 | Homozygous Familial Hypercholesterolemia | Withdrawn | 2018-04-12 | 2018-12-31 | ClinicalTrials.gov |
| NCT03455777 | Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial H… | Phase2 | Homozygous Familial Hypercholesterolemia | Withdrawn | 2018-04-12 | 2018-12-31 | ClinicalTrials.gov |
| NCT03455777 | Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial H… | Phase2 | Homozygous Familial Hypercholesterolemia | Withdrawn | 2018-04-12 | 2018-12-31 | ClinicalTrials.gov |
| NCT03506854 | Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Pati… | Phase1 | Renal Impairment | Completed | 2018-03-20 | 2018-10-11 | ClinicalTrials.gov |
| NCT03506854 | Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Pati… | Phase1 | Renal Impairment | Completed | 2018-03-20 | 2018-10-11 | ClinicalTrials.gov |
| NCT03506854 | Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Pati… | Phase1 | Renal Impairment | Completed | 2018-03-20 | 2018-10-11 | ClinicalTrials.gov |
| NCT03446144 | Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geo… | Phase2 | Geographic Atrophy | Withdrawn | 2018-03-16 | 2018-10-10 | ClinicalTrials.gov |
| NCT03446144 | Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geo… | Phase2 | Geographic Atrophy | Withdrawn | 2018-03-16 | 2018-10-10 | ClinicalTrials.gov |
| NCT03446144 | Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geo… | Phase2 | Geographic Atrophy | Withdrawn | 2018-03-16 | 2018-10-10 | ClinicalTrials.gov |
| NCT03385239 | Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceride… | Phase2 | Hypertriglyceridemia | Completed | 2018-01-30 | 2020-02-25 | ClinicalTrials.gov |
| NCT03385239 | Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceride… | Phase2 | Hypertriglyceridemia | Completed | 2018-01-30 | 2020-02-25 | ClinicalTrials.gov |
| NCT03385239 | Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceride… | Phase2 | Hypertriglyceridemia | Completed | 2018-01-30 | 2020-02-25 | ClinicalTrials.gov |
| NCT03393000 | Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed … | Phase3 | Glioblastoma | Terminated | 2018-01-16 | 2020-11-06 | ClinicalTrials.gov |
| NCT03393000 | Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed … | Phase3 | Glioblastoma | Terminated | 2018-01-16 | 2020-11-06 | ClinicalTrials.gov |
| NCT03393000 | Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed … | Phase3 | Glioblastoma | Terminated | 2018-01-16 | 2020-11-06 | ClinicalTrials.gov |
| NCT03358030 | A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Sta… | Phase2 | End-stage Renal Disease (ESRD) | Completed | 2017-12-26 | 2019-07-10 | ClinicalTrials.gov |
| NCT03358030 | A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Sta… | Phase2 | End-stage Renal Disease (ESRD) | Completed | 2017-12-26 | 2019-07-10 | ClinicalTrials.gov |
| NCT03358030 | A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Sta… | Phase2 | End-stage Renal Disease (ESRD) | Completed | 2017-12-26 | 2019-07-10 | ClinicalTrials.gov |
| NCT03360747 | Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial … | Phase2 | Familial Chylomicronemia Syndrome | Completed | 2017-12-21 | 2018-09-04 | ClinicalTrials.gov |
| NCT03360747 | Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial … | Phase2 | Familial Chylomicronemia Syndrome | Completed | 2017-12-21 | 2018-09-04 | ClinicalTrials.gov |
| NCT03371355 | Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes… | Phase2 | NAFLD | Completed | 2017-12-21 | 2020-02-24 | ClinicalTrials.gov |
| NCT03360747 | Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial … | Phase2 | Familial Chylomicronemia Syndrome | Completed | 2017-12-21 | 2018-09-04 | ClinicalTrials.gov |
| NCT03371355 | Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes… | Phase2 | NAFLD | Completed | 2017-12-21 | 2020-02-24 | ClinicalTrials.gov |
| NCT03371355 | Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes… | Phase2 | NAFLD | Completed | 2017-12-21 | 2020-02-24 | ClinicalTrials.gov |
| NCT03334214 | Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients W… | Phase2 | Hepatic Steatosis | Completed | 2017-11-03 | 2018-11-28 | ClinicalTrials.gov |
| NCT03334214 | Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients W… | Phase2 | Hepatic Steatosis | Completed | 2017-11-03 | 2018-11-28 | ClinicalTrials.gov |
| NCT03334214 | Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients W… | Phase2 | Hepatic Steatosis | Completed | 2017-11-03 | 2018-11-28 | ClinicalTrials.gov |
| NCT03104426 | EPO-4-Rhesus Study | Phase2 | Erythroblastosis, Fetal | Unknown | 2017-10-31 | 2020-08-01 | ClinicalTrials.gov |
| NCT03104426 | EPO-4-Rhesus Study | Phase2 | Erythroblastosis, Fetal | Unknown | 2017-10-31 | 2020-08-01 | ClinicalTrials.gov |
| NCT03104426 | EPO-4-Rhesus Study | Phase2 | Erythroblastosis, Fetal | Unknown | 2017-10-31 | 2020-08-01 | ClinicalTrials.gov |
| NCT03186989 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in… | Phase1 | Mild Alzheimer's Disease | Completed | 2017-10-12 | 2022-05-12 | ClinicalTrials.gov |
| NCT03186989 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in… | Phase1 | Mild Alzheimer's Disease | Completed | 2017-10-12 | 2022-05-12 | ClinicalTrials.gov |
| NCT03186989 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in… | Phase1 | Mild Alzheimer's Disease | Completed | 2017-10-12 | 2022-05-12 | ClinicalTrials.gov |
| NCT03263507 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Donidalorsen (I… | Phase1 | Healthy Volunteers | Completed | 2017-08-28 | 2018-10-09 | ClinicalTrials.gov |
| NCT03263507 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Donidalorsen (I… | Phase1 | Healthy Volunteers | Completed | 2017-08-28 | 2018-10-09 | ClinicalTrials.gov |
| NCT03263507 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Donidalorsen (I… | Phase1 | Healthy Volunteers | Completed | 2017-08-28 | 2018-10-09 | ClinicalTrials.gov |
| NCT03108469 | Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine | Phase2 | Chronic Migraine | Completed | 2017-08-01 | 2019-04-26 | ClinicalTrials.gov |
| NCT03108469 | Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine | Phase2 | Chronic Migraine | Completed | 2017-08-01 | 2019-04-26 | ClinicalTrials.gov |
| NCT03108469 | Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine | Phase2 | Chronic Migraine | Completed | 2017-08-01 | 2019-04-26 | ClinicalTrials.gov |
| NCT03092297 | Insufficient Cellular Oxygen in ICU Patients With Anaemia | — | Critical Care | Terminated | 2017-05-16 | 2022-12-01 | ClinicalTrials.gov |
| NCT03092297 | Insufficient Cellular Oxygen in ICU Patients With Anaemia | — | Critical Care | Terminated | 2017-05-16 | 2022-12-01 | ClinicalTrials.gov |
| NCT03092297 | Insufficient Cellular Oxygen in ICU Patients With Anaemia | — | Critical Care | Terminated | 2017-05-16 | 2022-12-01 | ClinicalTrials.gov |
| NCT03165864 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Adm… | Phase1 | Thalassemia | Completed | 2017-05-09 | 2018-09-25 | ClinicalTrials.gov |
| NCT03165864 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Adm… | Phase1 | Thalassemia | Completed | 2017-05-09 | 2018-09-25 | ClinicalTrials.gov |
| NCT03165864 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Adm… | Phase1 | Thalassemia | Completed | 2017-05-09 | 2018-09-25 | ClinicalTrials.gov |
| NCT03101878 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ionis AGT-LRx i… | Phase1 | Healthy Volunteers | Completed | 2017-04-05 | 2018-08-01 | ClinicalTrials.gov |
| NCT03101878 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ionis AGT-LRx i… | Phase1 | Healthy Volunteers | Completed | 2017-04-05 | 2018-08-01 | ClinicalTrials.gov |
| NCT03101878 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ionis AGT-LRx i… | Phase1 | Healthy Volunteers | Completed | 2017-04-05 | 2018-08-01 | ClinicalTrials.gov |
| NCT03070119 | Long-Term Evaluation of BIIB067 (Tofersen) | Phase3 | ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation | Completed | 2017-03-08 | 2024-08-12 | ClinicalTrials.gov |
| NCT03070119 | Long-Term Evaluation of BIIB067 (Tofersen) | Phase3 | ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation | Completed | 2017-03-08 | 2024-08-12 | ClinicalTrials.gov |
| NCT03070119 | Long-Term Evaluation of BIIB067 (Tofersen) | Phase3 | ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation | Completed | 2017-03-08 | 2024-08-12 | ClinicalTrials.gov |
| NCT03070782 | Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipop… | Phase2 | Elevated Lipoprotein(a) | Completed | 2017-03-07 | 2018-11-13 | ClinicalTrials.gov |
| NCT03070782 | Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipop… | Phase2 | Elevated Lipoprotein(a) | Completed | 2017-03-07 | 2018-11-13 | ClinicalTrials.gov |
| NCT03070782 | Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipop… | Phase2 | Elevated Lipoprotein(a) | Completed | 2017-03-07 | 2018-11-13 | ClinicalTrials.gov |
| NCT04067375 | Towards Routine HPA-screening In Pregnancy to Prevent FNAIT | — | Fetal and Neonatal Alloimmune Thrombocytopenia | Completed | 2017-03-01 | 2020-04-01 | ClinicalTrials.gov |
| NCT04067375 | Towards Routine HPA-screening In Pregnancy to Prevent FNAIT | — | Fetal and Neonatal Alloimmune Thrombocytopenia | Completed | 2017-03-01 | 2020-04-01 | ClinicalTrials.gov |
| NCT04067375 | Towards Routine HPA-screening In Pregnancy to Prevent FNAIT | — | Fetal and Neonatal Alloimmune Thrombocytopenia | Completed | 2017-03-01 | 2020-04-01 | ClinicalTrials.gov |
| NCT02981602 | Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in… | Phase2 | Hepatitis B | Completed | 2017-02-24 | 2019-12-26 | ClinicalTrials.gov |
| NCT02981602 | Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in… | Phase2 | Hepatitis B | Completed | 2017-02-24 | 2019-12-26 | ClinicalTrials.gov |
| NCT02981602 | Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in… | Phase2 | Hepatitis B | Completed | 2017-02-24 | 2019-12-26 | ClinicalTrials.gov |
| NCT03047369 | The Myelin Disorders Biorepository Project | — | Leukodystrophy | Recruiting | 2016-12-08 | 2030-12-08 | ClinicalTrials.gov |
| NCT03047369 | The Myelin Disorders Biorepository Project | — | Leukodystrophy | Recruiting | 2016-12-08 | 2030-12-08 | ClinicalTrials.gov |
| NCT03047369 | The Myelin Disorders Biorepository Project | — | Leukodystrophy | Recruiting | 2016-12-08 | 2030-12-08 | ClinicalTrials.gov |
| NCT02910635 | A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conduc… | Phase1 | Abnormalities, Cardiovascular | Completed | 2016-09-19 | 2016-12-20 | ClinicalTrials.gov |
| NCT02910635 | A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conduc… | Phase1 | Abnormalities, Cardiovascular | Completed | 2016-09-19 | 2016-12-20 | ClinicalTrials.gov |
| NCT02910635 | A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conduc… | Phase1 | Abnormalities, Cardiovascular | Completed | 2016-09-19 | 2016-12-20 | ClinicalTrials.gov |
| NCT02900027 | Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Heal… | Phase1 | Elevated Triglycerides (TG) | Completed | 2016-09-01 | 2018-04-30 | ClinicalTrials.gov |
| NCT02900027 | Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Heal… | Phase1 | Elevated Triglycerides (TG) | Completed | 2016-09-01 | 2018-04-30 | ClinicalTrials.gov |
| NCT02900027 | Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Heal… | Phase1 | Elevated Triglycerides (TG) | Completed | 2016-09-01 | 2018-04-30 | ClinicalTrials.gov |
| NCT03397017 | Transfusion Treatment in Patients With SCD | — | Anemia, Sickle Cell | Completed | 2016-07-01 | 2022-06-30 | ClinicalTrials.gov |
| NCT03397017 | Transfusion Treatment in Patients With SCD | — | Anemia, Sickle Cell | Completed | 2016-07-01 | 2022-06-30 | ClinicalTrials.gov |
| NCT03397017 | Transfusion Treatment in Patients With SCD | — | Anemia, Sickle Cell | Completed | 2016-07-01 | 2022-06-30 | ClinicalTrials.gov |
| NCT02824003 | Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Conte… | Phase2 | Type 2 Diabetes | Completed | 2016-04-01 | 2017-05-22 | ClinicalTrials.gov |
| NCT02824003 | Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Conte… | Phase2 | Type 2 Diabetes | Completed | 2016-04-01 | 2017-05-22 | ClinicalTrials.gov |
| NCT02736812 | Pre-hospital Administration of Lyophilized Plasma for Post-traumatic Coagulopat… | Phase3 | Shock Hemorrhagic | Completed | 2016-04-01 | 2019-11-30 | ClinicalTrials.gov |
| NCT02736812 | Pre-hospital Administration of Lyophilized Plasma for Post-traumatic Coagulopat… | Phase3 | Shock Hemorrhagic | Completed | 2016-04-01 | 2019-11-30 | ClinicalTrials.gov |
| NCT02824003 | Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Conte… | Phase2 | Type 2 Diabetes | Completed | 2016-04-01 | 2017-05-22 | ClinicalTrials.gov |
| NCT02736812 | Pre-hospital Administration of Lyophilized Plasma for Post-traumatic Coagulopat… | Phase3 | Shock Hemorrhagic | Completed | 2016-04-01 | 2019-11-30 | ClinicalTrials.gov |
| NCT02714764 | Evaluation of Outcome Metrics in Alexander Disease | — | Alexander Disease | Recruiting | 2016-01-26 | 2030-12-01 | ClinicalTrials.gov |
| NCT02714764 | Evaluation of Outcome Metrics in Alexander Disease | — | Alexander Disease | Recruiting | 2016-01-26 | 2030-12-01 | ClinicalTrials.gov |
| NCT02714764 | Evaluation of Outcome Metrics in Alexander Disease | — | Alexander Disease | Recruiting | 2016-01-26 | 2030-12-01 | ClinicalTrials.gov |
| NCT02623699 | An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study … | Phase3 | Amyotrophic Lateral Sclerosis | Completed | 2016-01-20 | 2021-07-16 | ClinicalTrials.gov |
| NCT02623699 | An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study … | Phase3 | Amyotrophic Lateral Sclerosis | Completed | 2016-01-20 | 2021-07-16 | ClinicalTrials.gov |
| NCT02623699 | An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study … | Phase3 | Amyotrophic Lateral Sclerosis | Completed | 2016-01-20 | 2021-07-16 | ClinicalTrials.gov |
| NCT02627820 | The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels … | Phase2 | Amyloidosis | Withdrawn | 2016-01-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT02627820 | The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels … | Phase2 | Amyloidosis | Withdrawn | 2016-01-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT02627820 | The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels … | Phase2 | Amyloidosis | Withdrawn | 2016-01-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT02527343 | The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Partic… | Phase2 | Familial Partial Lipodystrophy | Terminated | 2015-12-28 | 2019-11-13 | ClinicalTrials.gov |
| NCT02527343 | The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Partic… | Phase2 | Familial Partial Lipodystrophy | Terminated | 2015-12-28 | 2019-11-13 | ClinicalTrials.gov |
| NCT02527343 | The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Partic… | Phase2 | Familial Partial Lipodystrophy | Terminated | 2015-12-28 | 2019-11-13 | ClinicalTrials.gov |
| NCT02658175 | The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIR… | Phase3 | Familial Chylomicronemia Syndrome | Completed | 2015-12-23 | 2020-01-15 | ClinicalTrials.gov |
| NCT02658175 | The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIR… | Phase3 | Familial Chylomicronemia Syndrome | Completed | 2015-12-23 | 2020-01-15 | ClinicalTrials.gov |
| NCT02658175 | The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIR… | Phase3 | Familial Chylomicronemia Syndrome | Completed | 2015-12-23 | 2020-01-15 | ClinicalTrials.gov |
| NCT02957760 | Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydrox… | Phase2 | Central Retinal Vein Occlusion, Non-Ischemic | Unknown | 2015-12-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT02957760 | Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydrox… | Phase2 | Central Retinal Vein Occlusion, Non-Ischemic | Unknown | 2015-12-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT02957760 | Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydrox… | Phase2 | Central Retinal Vein Occlusion, Non-Ischemic | Unknown | 2015-12-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT02709850 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-L… | Phase1 | Hypertriglyceridemia | Completed | 2015-11-30 | 2017-06-26 | ClinicalTrials.gov |
| NCT02709850 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-L… | Phase1 | Hypertriglyceridemia | Completed | 2015-11-30 | 2017-06-26 | ClinicalTrials.gov |
| NCT02709850 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-L… | Phase1 | Hypertriglyceridemia | Completed | 2015-11-30 | 2017-06-26 | ClinicalTrials.gov |
| NCT03110887 | Monitoring Outcome in Neonatal Thrombocytopenia | — | Neonatal Thrombocytopenia | Completed | 2015-11-20 | 2016-11-09 | ClinicalTrials.gov |
| NCT03110887 | Monitoring Outcome in Neonatal Thrombocytopenia | — | Neonatal Thrombocytopenia | Completed | 2015-11-20 | 2016-11-09 | ClinicalTrials.gov |
| NCT03110887 | Monitoring Outcome in Neonatal Thrombocytopenia | — | Neonatal Thrombocytopenia | Completed | 2015-11-20 | 2016-11-09 | ClinicalTrials.gov |
| NCT02621008 | Mobile Phone-based Intervention for Promoting Healthy Habits and Weight Loss | Na | Diabetes | Unknown | 2015-11-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT02621008 | Mobile Phone-based Intervention for Promoting Healthy Habits and Weight Loss | Na | Diabetes | Unknown | 2015-11-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT02621008 | Mobile Phone-based Intervention for Promoting Healthy Habits and Weight Loss | Na | Diabetes | Unknown | 2015-11-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT02553889 | A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patie… | Phase2 | End-stage Renal Disease (ESRD) | Completed | 2015-10-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02553889 | A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patie… | Phase2 | End-stage Renal Disease (ESRD) | Completed | 2015-10-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02553889 | A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patie… | Phase2 | End-stage Renal Disease (ESRD) | Completed | 2015-10-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02583919 | Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabet… | Phase2 | Type 2 Diabetes | Completed | 2015-09-01 | 2017-05-11 | ClinicalTrials.gov |
| NCT02583919 | Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabet… | Phase2 | Type 2 Diabetes | Completed | 2015-09-01 | 2017-05-11 | ClinicalTrials.gov |
| NCT02583919 | Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabet… | Phase2 | Type 2 Diabetes | Completed | 2015-09-01 | 2017-05-11 | ClinicalTrials.gov |
| NCT02519036 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in … | Phase1 | Huntington's Disease | Completed | 2015-08-06 | 2017-11-08 | ClinicalTrials.gov |
| NCT02519036 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in … | Phase1 | Huntington's Disease | Completed | 2015-08-06 | 2017-11-08 | ClinicalTrials.gov |
| NCT02519036 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in … | Phase1 | Huntington's Disease | Completed | 2015-08-06 | 2017-11-08 | ClinicalTrials.gov |
| NCT02476019 | A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obes… | Phase2 | Obesity | Completed | 2015-06-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02476019 | A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obes… | Phase2 | Obesity | Completed | 2015-06-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02476019 | A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obes… | Phase2 | Obesity | Completed | 2015-06-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02414594 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LR… | Phase1 | Elevated Lipoprotein(a) | Completed | 2015-04-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02414594 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LR… | Phase1 | Elevated Lipoprotein(a) | Completed | 2015-04-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02414594 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LR… | Phase1 | Elevated Lipoprotein(a) | Completed | 2015-04-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02414490 | IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength … | — | Chronic Inflammatory Demyelinating Polyneuropathy | Completed | 2015-03-01 | 2020-05-01 | ClinicalTrials.gov |
| NCT02414490 | IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength … | — | Chronic Inflammatory Demyelinating Polyneuropathy | Completed | 2015-03-01 | 2020-05-01 | ClinicalTrials.gov |
| NCT02414490 | IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength … | — | Chronic Inflammatory Demyelinating Polyneuropathy | Completed | 2015-03-01 | 2020-05-01 | ClinicalTrials.gov |
| NCT02300233 | The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patient… | Phase3 | Hypertriglyceridemia | Completed | 2015-02-05 | 2017-01-24 | ClinicalTrials.gov |
| NCT02300233 | The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patient… | Phase3 | Hypertriglyceridemia | Completed | 2015-02-05 | 2017-01-24 | ClinicalTrials.gov |
| NCT02300233 | The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patient… | Phase3 | Hypertriglyceridemia | Completed | 2015-02-05 | 2017-01-24 | ClinicalTrials.gov |
| NCT02149472 | Towards Better Prognostic and Diagnostic Strategies for Haemostatic Changes Dur… | — | Postpartum Haemorrhage | Completed | 2015-02-04 | 2018-04-18 | ClinicalTrials.gov |
| NCT02149472 | Towards Better Prognostic and Diagnostic Strategies for Haemostatic Changes Dur… | — | Postpartum Haemorrhage | Completed | 2015-02-04 | 2018-04-18 | ClinicalTrials.gov |
| NCT02149472 | Towards Better Prognostic and Diagnostic Strategies for Haemostatic Changes Dur… | — | Postpartum Haemorrhage | Completed | 2015-02-04 | 2018-04-18 | ClinicalTrials.gov |
| NCT02342171 | Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Gu… | Phase2 | Hemorrhagic Fever, Ebola | Completed | 2015-02-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT02342171 | Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Gu… | Phase2 | Hemorrhagic Fever, Ebola | Completed | 2015-02-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT02342171 | Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Gu… | Phase2 | Hemorrhagic Fever, Ebola | Completed | 2015-02-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT02211209 | The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patie… | Phase3 | Familial Chylomicronemia Syndrome | Completed | 2014-12-01 | 2017-03-28 | ClinicalTrials.gov |
| NCT02312011 | A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With … | Phase1 | Myotonic Dystrophy Type 1 | Completed | 2014-12-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02211209 | The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patie… | Phase3 | Familial Chylomicronemia Syndrome | Completed | 2014-12-01 | 2017-03-28 | ClinicalTrials.gov |
| NCT02211209 | The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patie… | Phase3 | Familial Chylomicronemia Syndrome | Completed | 2014-12-01 | 2017-03-28 | ClinicalTrials.gov |
| NCT02312011 | A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With … | Phase1 | Myotonic Dystrophy Type 1 | Completed | 2014-12-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02312011 | A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With … | Phase1 | Myotonic Dystrophy Type 1 | Completed | 2014-12-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02259478 | Isoagglutinins in the Development of IVIG-associated Hemolysis | — | Immunoglobulins, Intravenous | Completed | 2014-10-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02259478 | Isoagglutinins in the Development of IVIG-associated Hemolysis | — | Immunoglobulins, Intravenous | Completed | 2014-10-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02259478 | Isoagglutinins in the Development of IVIG-associated Hemolysis | — | Immunoglobulins, Intravenous | Completed | 2014-10-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02175004 | Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Fami… | Phase3 | FAP | Completed | 2014-06-26 | 2021-01-07 | ClinicalTrials.gov |
| NCT02175004 | Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Fami… | Phase3 | FAP | Completed | 2014-06-26 | 2021-01-07 | ClinicalTrials.gov |
| NCT02175004 | Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Fami… | Phase3 | FAP | Completed | 2014-06-26 | 2021-01-07 | ClinicalTrials.gov |
| NCT02160899 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx i… | Phase2 | Elevated Lipoprotein(a) | Completed | 2014-06-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02176239 | Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immu… | — | Primary Immunodeficiency Disease (PIDD) | Completed | 2014-06-01 | 2019-08-01 | ClinicalTrials.gov |
| NCT02160899 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx i… | Phase2 | Elevated Lipoprotein(a) | Completed | 2014-06-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02176239 | Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immu… | — | Primary Immunodeficiency Disease (PIDD) | Completed | 2014-06-01 | 2019-08-01 | ClinicalTrials.gov |
| NCT02176239 | Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immu… | — | Primary Immunodeficiency Disease (PIDD) | Completed | 2014-06-01 | 2019-08-01 | ClinicalTrials.gov |
| NCT02160899 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx i… | Phase2 | Elevated Lipoprotein(a) | Completed | 2014-06-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT01968265 | Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes | Phase2 | Type 2 Diabetes Mellitus | Completed | 2013-10-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT01968265 | Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes | Phase2 | Type 2 Diabetes Mellitus | Completed | 2013-10-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT01968265 | Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes | Phase2 | Type 2 Diabetes Mellitus | Completed | 2013-10-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT01918865 | Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes | Phase2 | Type 2 Diabetes Mellitus | Completed | 2013-08-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01918865 | Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes | Phase2 | Type 2 Diabetes Mellitus | Completed | 2013-08-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01918865 | Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes | Phase2 | Type 2 Diabetes Mellitus | Completed | 2013-08-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01885260 | Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes | Phase2 | Type 2 Diabetes Mellitus | Completed | 2013-07-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01885260 | Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes | Phase2 | Type 2 Diabetes Mellitus | Completed | 2013-07-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01885260 | Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes | Phase2 | Type 2 Diabetes Mellitus | Completed | 2013-07-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01883921 | Gamma Globulin Observations and Outcomes Database for Patients With Primary Imm… | — | Primary Immune Deficiency Disorder | Terminated | 2013-06-01 | 2019-08-01 | ClinicalTrials.gov |
| NCT01883921 | Gamma Globulin Observations and Outcomes Database for Patients With Primary Imm… | — | Primary Immune Deficiency Disorder | Terminated | 2013-06-01 | 2019-08-01 | ClinicalTrials.gov |
| NCT01883921 | Gamma Globulin Observations and Outcomes Database for Patients With Primary Imm… | — | Primary Immune Deficiency Disorder | Terminated | 2013-06-01 | 2019-08-01 | ClinicalTrials.gov |
| NCT01839604 | A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastat… | Phase1 | Advanced Adult Hepatocellular Carcinoma | Completed | 2013-05-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01839604 | A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastat… | Phase1 | Advanced Adult Hepatocellular Carcinoma | Completed | 2013-05-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01839604 | A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastat… | Phase1 | Advanced Adult Hepatocellular Carcinoma | Completed | 2013-05-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01737398 | Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy | Phase2 | FAP | Completed | 2013-03-15 | 2017-11-07 | ClinicalTrials.gov |
| NCT01737398 | Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy | Phase2 | FAP | Completed | 2013-03-15 | 2017-11-07 | ClinicalTrials.gov |
| NCT01737398 | Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy | Phase2 | FAP | Completed | 2013-03-15 | 2017-11-07 | ClinicalTrials.gov |
| NCT01774331 | Gamma Globulin Observations and Outcomes Database for Specific Home Infusion Ev… | — | Intravenous Immunoglobulin (IVIg) Therapy in a Home Infusion Setting | Terminated | 2012-11-01 | 2019-08-01 | ClinicalTrials.gov |
| NCT01774331 | Gamma Globulin Observations and Outcomes Database for Specific Home Infusion Ev… | — | Intravenous Immunoglobulin (IVIg) Therapy in a Home Infusion Setting | Terminated | 2012-11-01 | 2019-08-01 | ClinicalTrials.gov |
| NCT01774331 | Gamma Globulin Observations and Outcomes Database for Specific Home Infusion Ev… | — | Intravenous Immunoglobulin (IVIg) Therapy in a Home Infusion Setting | Terminated | 2012-11-01 | 2019-08-01 | ClinicalTrials.gov |
| NCT01710852 | Antiarrhythmic and Symptomatic Effect of ISIS CRP Rx Targeting CRP in Paroxysma… | Phase2 | Paroxysmal Atrial Fibrillation | Completed | 2012-10-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01710852 | Antiarrhythmic and Symptomatic Effect of ISIS CRP Rx Targeting CRP in Paroxysma… | Phase2 | Paroxysmal Atrial Fibrillation | Completed | 2012-10-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01638416 | Standard Issue Transfusion Versus Fresher Red Blood Cell Use in Intensive Care-… | Phase3 | Transfusion | Completed | 2012-10-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT01638416 | Standard Issue Transfusion Versus Fresher Red Blood Cell Use in Intensive Care-… | Phase3 | Transfusion | Completed | 2012-10-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT01638416 | Standard Issue Transfusion Versus Fresher Red Blood Cell Use in Intensive Care-… | Phase3 | Transfusion | Completed | 2012-10-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT01710852 | Antiarrhythmic and Symptomatic Effect of ISIS CRP Rx Targeting CRP in Paroxysma… | Phase2 | Paroxysmal Atrial Fibrillation | Completed | 2012-10-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01713361 | Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx … | Phase2 | Venous Thromboembolism | Completed | 2012-10-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01713361 | Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx … | Phase2 | Venous Thromboembolism | Completed | 2012-10-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01713361 | Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx … | Phase2 | Venous Thromboembolism | Completed | 2012-10-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01647308 | Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes | Phase2 | Type 2 Diabetes | Terminated | 2012-07-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01647308 | Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes | Phase2 | Type 2 Diabetes | Terminated | 2012-07-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01647308 | Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes | Phase2 | Type 2 Diabetes | Terminated | 2012-07-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01555060 | Hemoglobin and Iron Recovery Study | Phase2 | Recovery of Hemoglobin and Iron Stores After Blood Donation | Completed | 2012-03-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01555060 | Hemoglobin and Iron Recovery Study | Phase2 | Recovery of Hemoglobin and Iron Stores After Blood Donation | Completed | 2012-03-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01555060 | Hemoglobin and Iron Recovery Study | Phase2 | Recovery of Hemoglobin and Iron Stores After Blood Donation | Completed | 2012-03-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01563302 | Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to … | Phase1 | Advanced Cancers | Completed | 2012-02-27 | 2016-03-23 | ClinicalTrials.gov |
| NCT01563302 | Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to … | Phase1 | Advanced Cancers | Completed | 2012-02-27 | 2016-03-23 | ClinicalTrials.gov |
| NCT01563302 | Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to … | Phase1 | Advanced Cancers | Completed | 2012-02-27 | 2016-03-23 | ClinicalTrials.gov |
| NCT01465347 | Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozo… | Phase1 | Glioblastoma | Completed | 2012-02-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT01465347 | Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozo… | Phase1 | Glioblastoma | Completed | 2012-02-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT01529424 | Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertri… | Phase2 | Hypertriglyceridemia | Completed | 2012-02-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01529424 | Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertri… | Phase2 | Hypertriglyceridemia | Completed | 2012-02-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01529424 | Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertri… | Phase2 | Hypertriglyceridemia | Completed | 2012-02-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01465347 | Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozo… | Phase1 | Glioblastoma | Completed | 2012-02-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT01436019 | Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic Arthritis | — | Juvenile Idiopathic Arthritis | Unknown | 2011-10-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01436019 | Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic Arthritis | — | Juvenile Idiopathic Arthritis | Unknown | 2011-10-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01436019 | Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic Arthritis | — | Juvenile Idiopathic Arthritis | Unknown | 2011-10-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01414881 | Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism i… | Phase1 | Healthy Volunteer | Completed | 2011-09-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01414881 | Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism i… | Phase1 | Healthy Volunteer | Completed | 2011-09-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01414881 | Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism i… | Phase1 | Healthy Volunteer | Completed | 2011-09-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01414101 | Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Ar… | Phase2 | Rheumatoid Arthritis | Completed | 2011-08-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01414101 | Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Ar… | Phase2 | Rheumatoid Arthritis | Completed | 2011-08-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01414101 | Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Ar… | Phase2 | Rheumatoid Arthritis | Completed | 2011-08-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT02245321 | Strategies to Reduce Iron Deficiency | Na | Iron Deficiency | Completed | 2011-06-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT02245321 | Strategies to Reduce Iron Deficiency | Na | Iron Deficiency | Completed | 2011-06-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT02245321 | Strategies to Reduce Iron Deficiency | Na | Iron Deficiency | Completed | 2011-06-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01299298 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Do… | Phase1 | Healthy Volunteer | Completed | 2011-01-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01299298 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Do… | Phase1 | Healthy Volunteer | Completed | 2011-01-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01299298 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Do… | Phase1 | Healthy Volunteer | Completed | 2011-01-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01525459 | Gene Expression, Immunological Status and Metabolome in Glioma Patients | — | Glioma | Unknown | 2010-12-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01525459 | Gene Expression, Immunological Status and Metabolome in Glioma Patients | — | Glioma | Unknown | 2010-12-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01525459 | Gene Expression, Immunological Status and Metabolome in Glioma Patients | — | Glioma | Unknown | 2010-12-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01234038 | Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin … | Phase1 | Non-small Cell Lung Cancer | Completed | 2010-11-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01234038 | Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin … | Phase1 | Non-small Cell Lung Cancer | Completed | 2010-11-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01234025 | Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel an… | Phase1 | Castrate-Resistant Prostate Cancer | Completed | 2010-11-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01234025 | Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel an… | Phase1 | Castrate-Resistant Prostate Cancer | Completed | 2010-11-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01234025 | Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel an… | Phase1 | Castrate-Resistant Prostate Cancer | Completed | 2010-11-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01234038 | Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin … | Phase1 | Non-small Cell Lung Cancer | Completed | 2010-11-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01133366 | A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on… | Phase1 | Healthy | Completed | 2010-05-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01133366 | A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on… | Phase1 | Healthy | Completed | 2010-05-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01133366 | A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on… | Phase1 | Healthy | Completed | 2010-05-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01090661 | A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducte… | Phase1 | Healthy | Completed | 2010-03-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01050881 | Notification of Donors With Positive Microbiology Markers | — | Human Immunodeficiency Virus | Completed | 2010-03-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01050881 | Notification of Donors With Positive Microbiology Markers | — | Human Immunodeficiency Virus | Completed | 2010-03-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01090661 | A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducte… | Phase1 | Healthy | Completed | 2010-03-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01090661 | A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducte… | Phase1 | Healthy | Completed | 2010-03-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01050881 | Notification of Donors With Positive Microbiology Markers | — | Human Immunodeficiency Virus | Completed | 2010-03-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01041222 | Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyot… | Phase1 | Familial Amyotrophic Lateral Sclerosis | Completed | 2010-01-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01061814 | A Study to Evaluate 3 Different Dosing Regimens of Mipomersen Administered Via … | Phase1 | Healthy Volunteer | Completed | 2010-01-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01041222 | Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyot… | Phase1 | Familial Amyotrophic Lateral Sclerosis | Completed | 2010-01-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01041222 | Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyot… | Phase1 | Familial Amyotrophic Lateral Sclerosis | Completed | 2010-01-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01061814 | A Study to Evaluate 3 Different Dosing Regimens of Mipomersen Administered Via … | Phase1 | Healthy Volunteer | Completed | 2010-01-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01061814 | A Study to Evaluate 3 Different Dosing Regimens of Mipomersen Administered Via … | Phase1 | Healthy Volunteer | Completed | 2010-01-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01023165 | Effects of Intensive Bolus Intravenous Insulin Delivery on Metabolic Integrity … | Phase3 | Diabetes Mellitus | Unknown | 2009-11-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT01023165 | Effects of Intensive Bolus Intravenous Insulin Delivery on Metabolic Integrity … | Phase3 | Diabetes Mellitus | Unknown | 2009-11-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT01023165 | Effects of Intensive Bolus Intravenous Insulin Delivery on Metabolic Integrity … | Phase3 | Diabetes Mellitus | Unknown | 2009-11-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT00944112 | Restrictive and Liberal Transfusion Strategies in Intensive Care | Na | Intensive Care | Completed | 2009-08-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00944112 | Restrictive and Liberal Transfusion Strategies in Intensive Care | Na | Intensive Care | Completed | 2009-08-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00944112 | Restrictive and Liberal Transfusion Strategies in Intensive Care | Na | Intensive Care | Completed | 2009-08-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01021800 | Modulation of the Immune Response in Patients With Pancreatic Tubular Adenocarc… | Phase2 | Pancreatic Tubular Adenocarcinoma | Unknown | 2009-04-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01021800 | Modulation of the Immune Response in Patients With Pancreatic Tubular Adenocarc… | Phase2 | Pancreatic Tubular Adenocarcinoma | Unknown | 2009-04-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01021800 | Modulation of the Immune Response in Patients With Pancreatic Tubular Adenocarc… | Phase2 | Pancreatic Tubular Adenocarcinoma | Unknown | 2009-04-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00826930 | Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Saf… | Phase1 | High Grade Glioma | Terminated | 2009-03-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00826930 | Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Saf… | Phase1 | High Grade Glioma | Terminated | 2009-03-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00826930 | Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Saf… | Phase1 | High Grade Glioma | Terminated | 2009-03-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00947102 | Influence of Gemcitabine Treatment on Immunological and Serological Profile in … | — | Pancreatic Tubular Adenocarcinoma | Unknown | 2009-02-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00947102 | Influence of Gemcitabine Treatment on Immunological and Serological Profile in … | — | Pancreatic Tubular Adenocarcinoma | Unknown | 2009-02-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00947102 | Influence of Gemcitabine Treatment on Immunological and Serological Profile in … | — | Pancreatic Tubular Adenocarcinoma | Unknown | 2009-02-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01616329 | R-FACT Study:Risk Factors for Alloimmunization After Red Blood Cell Transfusions | — | Hemolysis | Completed | 2009-01-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT00794664 | Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia … | Phase3 | Hypercholesterolemia | Completed | 2009-01-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00836225 | Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in He… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2009-01-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT00794664 | Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia … | Phase3 | Hypercholesterolemia | Completed | 2009-01-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00836225 | Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in He… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2009-01-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01616329 | R-FACT Study:Risk Factors for Alloimmunization After Red Blood Cell Transfusions | — | Hemolysis | Completed | 2009-01-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT00794664 | Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia … | Phase3 | Hypercholesterolemia | Completed | 2009-01-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00836225 | Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in He… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2009-01-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01616329 | R-FACT Study:Risk Factors for Alloimmunization After Red Blood Cell Transfusions | — | Hemolysis | Completed | 2009-01-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT00770146 | Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk … | Phase3 | Hypercholesterolemia | Completed | 2008-11-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00770146 | Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk … | Phase3 | Hypercholesterolemia | Completed | 2008-11-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00770146 | Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk … | Phase3 | Hypercholesterolemia | Completed | 2008-11-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00707746 | Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Ri… | Phase2 | Metabolic Diseases | Completed | 2008-10-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT00755950 | Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silym… | Phase2 | Acute Hepatitis A | Terminated | 2008-10-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT00755950 | Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silym… | Phase2 | Acute Hepatitis A | Terminated | 2008-10-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT00707746 | Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Ri… | Phase2 | Metabolic Diseases | Completed | 2008-10-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT00755950 | Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silym… | Phase2 | Acute Hepatitis A | Terminated | 2008-10-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT00707746 | Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Ri… | Phase2 | Metabolic Diseases | Completed | 2008-10-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT01052649 | Gene Expression Monitoring of Mononuclear Cells (MNC) Subpopulations and Immuno… | — | Gene Expression | Completed | 2008-08-01 | — | ClinicalTrials.gov |
| NCT00774748 | Once Weekly Subcutaneous Ports for the Administration of Anticoagulants | Na | Venous Thromboembolism | Completed | 2008-08-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT01052649 | Gene Expression Monitoring of Mononuclear Cells (MNC) Subpopulations and Immuno… | — | Gene Expression | Completed | 2008-08-01 | — | ClinicalTrials.gov |
| NCT00774748 | Once Weekly Subcutaneous Ports for the Administration of Anticoagulants | Na | Venous Thromboembolism | Completed | 2008-08-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00725881 | Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (… | Phase1 | Intermittent Claudication | Completed | 2008-08-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00725881 | Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (… | Phase1 | Intermittent Claudication | Completed | 2008-08-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00725881 | Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (… | Phase1 | Intermittent Claudication | Completed | 2008-08-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00774748 | Once Weekly Subcutaneous Ports for the Administration of Anticoagulants | Na | Venous Thromboembolism | Completed | 2008-08-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT01052649 | Gene Expression Monitoring of Mononuclear Cells (MNC) Subpopulations and Immuno… | — | Gene Expression | Completed | 2008-08-01 | — | ClinicalTrials.gov |
| NCT00706849 | Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hyp… | Phase3 | Heterozygous Familial Hypercholesterolemia | Completed | 2008-07-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00734240 | Safety and Tolerability of Single and Multiple Doses of ISIS 353512 in Healthy … | Phase1 | Inflammatory Diseases | Completed | 2008-07-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00734240 | Safety and Tolerability of Single and Multiple Doses of ISIS 353512 in Healthy … | Phase1 | Inflammatory Diseases | Completed | 2008-07-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00706849 | Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hyp… | Phase3 | Heterozygous Familial Hypercholesterolemia | Completed | 2008-07-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00734240 | Safety and Tolerability of Single and Multiple Doses of ISIS 353512 in Healthy … | Phase1 | Inflammatory Diseases | Completed | 2008-07-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00706849 | Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hyp… | Phase3 | Heterozygous Familial Hypercholesterolemia | Completed | 2008-07-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00725738 | Intracoronary Autologous Stem Cell Transplantation in ST Elevation Myocardial I… | Phase2 | Acute Myocardial Infarction | Unknown | 2008-05-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00725738 | Intracoronary Autologous Stem Cell Transplantation in ST Elevation Myocardial I… | Phase2 | Acute Myocardial Infarction | Unknown | 2008-05-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00725738 | Intracoronary Autologous Stem Cell Transplantation in ST Elevation Myocardial I… | Phase2 | Acute Myocardial Infarction | Unknown | 2008-05-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00694109 | An Open-label Extension Study to Assess the Long-term Safety and Efficacy of IS… | Phase3 | Lipid Metabolism, Inborn Errors | Completed | 2008-04-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT00694109 | An Open-label Extension Study to Assess the Long-term Safety and Efficacy of IS… | Phase3 | Lipid Metabolism, Inborn Errors | Completed | 2008-04-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT00694109 | An Open-label Extension Study to Assess the Long-term Safety and Efficacy of IS… | Phase3 | Lipid Metabolism, Inborn Errors | Completed | 2008-04-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT00519727 | Safety Study of ISIS 325568 in Healthy Volunteers | Phase1 | Type 2 Diabetes Mellitus | Completed | 2007-08-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00519727 | Safety Study of ISIS 325568 in Healthy Volunteers | Phase1 | Type 2 Diabetes Mellitus | Completed | 2007-08-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00519727 | Safety Study of ISIS 325568 in Healthy Volunteers | Phase1 | Type 2 Diabetes Mellitus | Completed | 2007-08-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00607373 | Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygo… | Phase3 | Lipid Metabolism, Inborn Errors | Completed | 2007-07-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00607373 | Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygo… | Phase3 | Lipid Metabolism, Inborn Errors | Completed | 2007-07-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00607373 | Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygo… | Phase3 | Lipid Metabolism, Inborn Errors | Completed | 2007-07-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00477594 | Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholest… | Phase2 | Lipid Metabolism, Inborn Errors | Completed | 2007-05-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00477594 | Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholest… | Phase2 | Lipid Metabolism, Inborn Errors | Completed | 2007-05-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00477594 | Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholest… | Phase2 | Lipid Metabolism, Inborn Errors | Completed | 2007-05-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00455598 | Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mell… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2007-02-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00455598 | Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mell… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2007-02-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00455598 | Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mell… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2007-02-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT01029639 | Effects of Pulsatile Intravenous Insulin Delivery on Hypoglycemic Unawareness | Phase2 | Hypoglycemia | Withdrawn | 2007-01-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT01029639 | Effects of Pulsatile Intravenous Insulin Delivery on Hypoglycemic Unawareness | Phase2 | Hypoglycemia | Withdrawn | 2007-01-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT01029639 | Effects of Pulsatile Intravenous Insulin Delivery on Hypoglycemic Unawareness | Phase2 | Hypoglycemia | Withdrawn | 2007-01-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00365781 | Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715 | Phase1 | Type 2 Diabetes Mellitus | Completed | 2006-08-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00365781 | Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715 | Phase1 | Type 2 Diabetes Mellitus | Completed | 2006-08-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00365781 | Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715 | Phase1 | Type 2 Diabetes Mellitus | Completed | 2006-08-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00362180 | Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration | Phase2 | Lipid Metabolism, Inborn Errors | Completed | 2006-07-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00362180 | Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration | Phase2 | Lipid Metabolism, Inborn Errors | Completed | 2006-07-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00362180 | Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration | Phase2 | Lipid Metabolism, Inborn Errors | Completed | 2006-07-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00629018 | Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiom… | Phase2 | Dilated Cardiomyopathy | Completed | 2006-05-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT00629018 | Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiom… | Phase2 | Dilated Cardiomyopathy | Completed | 2006-05-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT00327626 | Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabete… | Phase2 | Type 2 Diabetes Mellitus | Withdrawn | 2006-05-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00327626 | Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabete… | Phase2 | Type 2 Diabetes Mellitus | Withdrawn | 2006-05-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00629018 | Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiom… | Phase2 | Dilated Cardiomyopathy | Completed | 2006-05-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT00327626 | Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabete… | Phase2 | Type 2 Diabetes Mellitus | Withdrawn | 2006-05-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00233246 | Fresh-Frozen Plasma Infusions to Reduce Risk of Bleeding Related to Invasive Pr… | Phase3 | Blood Coagulation Disorders | Withdrawn | 2006-03-01 | — | ClinicalTrials.gov |
| NCT00233246 | Fresh-Frozen Plasma Infusions to Reduce Risk of Bleeding Related to Invasive Pr… | Phase3 | Blood Coagulation Disorders | Withdrawn | 2006-03-01 | — | ClinicalTrials.gov |
| NCT00233246 | Fresh-Frozen Plasma Infusions to Reduce Risk of Bleeding Related to Invasive Pr… | Phase3 | Blood Coagulation Disorders | Withdrawn | 2006-03-01 | — | ClinicalTrials.gov |
| NCT00281008 | Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia… | Phase2 | Hypercholesterolemia, Familial | Completed | 2006-02-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00281008 | Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia… | Phase2 | Hypercholesterolemia, Familial | Completed | 2006-02-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00281008 | Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia… | Phase2 | Hypercholesterolemia, Familial | Completed | 2006-02-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00280995 | Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholest… | Phase2 | Hypercholesterolemia, Familial | Completed | 2006-01-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00280995 | Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholest… | Phase2 | Hypercholesterolemia, Familial | Completed | 2006-01-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00280995 | Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholest… | Phase2 | Hypercholesterolemia, Familial | Completed | 2006-01-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00287651 | Effects of Pulsatile IV Insulin Delivery on Diabetic Retinopathy in Patients Wi… | Phase2 | Diabetes Mellitus, With Complications | Terminated | 2005-11-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00287651 | Effects of Pulsatile IV Insulin Delivery on Diabetic Retinopathy in Patients Wi… | Phase2 | Diabetes Mellitus, With Complications | Terminated | 2005-11-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00330200 | Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism an… | Phase2 | Type 2 Diabetes Mellitus | Terminated | 2005-11-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00287651 | Effects of Pulsatile IV Insulin Delivery on Diabetic Retinopathy in Patients Wi… | Phase2 | Diabetes Mellitus, With Complications | Terminated | 2005-11-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00330200 | Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism an… | Phase2 | Type 2 Diabetes Mellitus | Terminated | 2005-11-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00330200 | Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism an… | Phase2 | Type 2 Diabetes Mellitus | Terminated | 2005-11-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00231569 | Dose-escalating Safety Study in Subjects on Stable Statin Therapy | Phase2 | Hypercholesterolemia | Completed | 2005-09-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00231569 | Dose-escalating Safety Study in Subjects on Stable Statin Therapy | Phase2 | Hypercholesterolemia | Completed | 2005-09-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00231569 | Dose-escalating Safety Study in Subjects on Stable Statin Therapy | Phase2 | Hypercholesterolemia | Completed | 2005-09-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00216463 | Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With … | Phase2 | Hypercholesterolemia | Completed | 2005-08-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00216463 | Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With … | Phase2 | Hypercholesterolemia | Completed | 2005-08-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00216463 | Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With … | Phase2 | Hypercholesterolemia | Completed | 2005-08-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00228904 | Effects of Pulsatile Intravenous Insulin Delivery on Diabetic Neuropathy in pAT… | Phase2 | Diabetic Neuropathy | Withdrawn | 2005-02-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00228904 | Effects of Pulsatile Intravenous Insulin Delivery on Diabetic Neuropathy in pAT… | Phase2 | Diabetic Neuropathy | Withdrawn | 2005-02-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00228904 | Effects of Pulsatile Intravenous Insulin Delivery on Diabetic Neuropathy in pAT… | Phase2 | Diabetic Neuropathy | Withdrawn | 2005-02-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00128713 | Optimal Platelet Dose Strategy for Management of Thrombocytopenia | Phase3 | Thrombocytopenia | Completed | 2004-07-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00128713 | Optimal Platelet Dose Strategy for Management of Thrombocytopenia | Phase3 | Thrombocytopenia | Completed | 2004-07-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00128713 | Optimal Platelet Dose Strategy for Management of Thrombocytopenia | Phase3 | Thrombocytopenia | Completed | 2004-07-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00228891 | Effects of Pulsatile Insulin Delivery on Diabetic Neuropathy in Patients With T… | Phase2 | Diabetes Mellitus, With Complications | Terminated | 2004-02-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00228891 | Effects of Pulsatile Insulin Delivery on Diabetic Neuropathy in Patients With T… | Phase2 | Diabetes Mellitus, With Complications | Terminated | 2004-02-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00228891 | Effects of Pulsatile Insulin Delivery on Diabetic Neuropathy in Patients With T… | Phase2 | Diabetes Mellitus, With Complications | Terminated | 2004-02-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00062816 | Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic … | Phase1 | Hepatitis C, Chronic | Completed | 2003-06-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT00062816 | Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic … | Phase1 | Hepatitis C, Chronic | Completed | 2003-06-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT00062816 | Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic … | Phase1 | Hepatitis C, Chronic | Completed | 2003-06-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT00063830 | ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Eff… | Phase2 | Ulcerative Colitis | Completed | 2003-04-03 | 2004-10-11 | ClinicalTrials.gov |
| NCT00063830 | ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Eff… | Phase2 | Ulcerative Colitis | Completed | 2003-04-03 | 2004-10-11 | ClinicalTrials.gov |
| NCT00063830 | ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Eff… | Phase2 | Ulcerative Colitis | Completed | 2003-04-03 | 2004-10-11 | ClinicalTrials.gov |
| NCT00330330 | Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabete… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2003-02-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00330330 | Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabete… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2003-02-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00330330 | Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabete… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2003-02-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00063414 | ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effe… | Phase2 | Ulcerative Colitis | Completed | 2002-11-20 | 2005-03-24 | ClinicalTrials.gov |
| NCT00063414 | ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effe… | Phase2 | Ulcerative Colitis | Completed | 2002-11-20 | 2005-03-24 | ClinicalTrials.gov |
| NCT00063414 | ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effe… | Phase2 | Ulcerative Colitis | Completed | 2002-11-20 | 2005-03-24 | ClinicalTrials.gov |
| NCT00048295 | Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease | Phase3 | Crohn's Disease | Completed | 2002-05-01 | — | ClinicalTrials.gov |
| NCT00048295 | Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease | Phase3 | Crohn's Disease | Completed | 2002-05-01 | — | ClinicalTrials.gov |
| NCT00048295 | Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease | Phase3 | Crohn's Disease | Completed | 2002-05-01 | — | ClinicalTrials.gov |
| NCT00048321 | ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthr… | Phase2 | Rheumatoid Arthritis | Completed | 2002-01-01 | 2003-02-01 | ClinicalTrials.gov |
| NCT00048321 | ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthr… | Phase2 | Rheumatoid Arthritis | Completed | 2002-01-01 | 2003-02-01 | ClinicalTrials.gov |
| NCT00048321 | ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthr… | Phase2 | Rheumatoid Arthritis | Completed | 2002-01-01 | 2003-02-01 | ClinicalTrials.gov |
| NCT00035945 | ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chr… | Phase2 | Hepatitis C, Chronic | Completed | 2001-10-01 | 2004-05-01 | ClinicalTrials.gov |
| NCT00035945 | ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chr… | Phase2 | Hepatitis C, Chronic | Completed | 2001-10-01 | 2004-05-01 | ClinicalTrials.gov |
| NCT00035945 | ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chr… | Phase2 | Hepatitis C, Chronic | Completed | 2001-10-01 | 2004-05-01 | ClinicalTrials.gov |
| NCT00048113 | Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease | Phase3 | Crohn's Disease | Completed | 2001-01-10 | 2002-04-27 | ClinicalTrials.gov |
| NCT00048113 | Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease | Phase3 | Crohn's Disease | Completed | 2001-01-10 | 2002-04-27 | ClinicalTrials.gov |
| NCT00048113 | Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease | Phase3 | Crohn's Disease | Completed | 2001-01-10 | 2002-04-27 | ClinicalTrials.gov |
| NCT00017407 | Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With … | Phase3 | Lung Cancer | Completed | 2000-10-13 | 2002-09-09 | ClinicalTrials.gov |
| NCT00017407 | Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With … | Phase3 | Lung Cancer | Completed | 2000-10-13 | 2002-09-09 | ClinicalTrials.gov |
| NCT00017407 | Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With … | Phase3 | Lung Cancer | Completed | 2000-10-13 | 2002-09-09 | ClinicalTrials.gov |
| NCT00005594 | ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas | Phase2 | Pancreatic Cancer | Completed | 2000-07-01 | — | ClinicalTrials.gov |
| NCT00005594 | ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas | Phase2 | Pancreatic Cancer | Completed | 2000-07-01 | — | ClinicalTrials.gov |
| NCT00005594 | ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas | Phase2 | Pancreatic Cancer | Completed | 2000-07-01 | — | ClinicalTrials.gov |
Total clinical trials: 756
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| obudanersen | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| Donidalorsen | Other | Preclinical | Hereditary Angioedema | AVAILABLE | NCT06415448 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| Placebo | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| ION717 | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| Olaparib | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06909825 |
| FPI-2265 | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06909825 |
| Olezarsen | Other | Phase PHASE3 | Familial Chylomicronemia Syndrome | RECRUITING | NCT07727538 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Olezarsen | Other | Phase PHASE3 | Familial Chylomicronemia Syndrome | RECRUITING | NCT07727538 |
| Placebo | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis | ACTIVE_NOT_RECRUITING | NCT04768972 |
| ION363 | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis | ACTIVE_NOT_RECRUITING | NCT04768972 |
| Olaparib | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06909825 |
| FPI-2265 | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06909825 |
| sapablursen | Other | Phase PHASE2 | Phlebotomy Dependent Polycythemia Vera | COMPLETED | NCT05143957 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION775 | Other | Phase PHASE2 | Hypertriglyceridemia | RECRUITING | NCT07604974 |
| ION775 | Other | Phase PHASE2 | Hypertriglyceridemia | RECRUITING | NCT07604974 |
| Olaparib | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06909825 |
| FPI-2265 | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06909825 |
| ION775 | Other | Phase PHASE2 | Hypertriglyceridemia | RECRUITING | NCT07604974 |
| sapablursen | Other | Phase PHASE2 | Phlebotomy Dependent Polycythemia Vera | ACTIVE_NOT_RECRUITING | NCT05143957 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| ION775 | Other | Phase PHASE2 | Hypertriglyceridemia | RECRUITING | NCT07604974 |
| ION775 | Other | Phase PHASE2 | Hypertriglyceridemia | RECRUITING | NCT07604974 |
| ION775 | Other | Phase PHASE2 | Hypertriglyceridemia | RECRUITING | NCT07604974 |
| ION775 | Other | Phase PHASE2 | Hypertriglyceridemia | RECRUITING | NCT07604974 |
| ION775 | Other | Phase PHASE2 | Hypertriglyceridemia | RECRUITING | NCT07604974 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| Club 25 | Other | Approved | Blood Donation | COMPLETED | NCT06138899 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| Club 25 | Other | Approved | Blood Donation | COMPLETED | NCT06138899 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| Club 25 | Other | Approved | Blood Donation | COMPLETED | NCT06138899 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| Club 25 | Other | Approved | Blood Donation | COMPLETED | NCT06138899 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| Club 25 | Other | Approved | Blood Donation | COMPLETED | NCT06138899 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| Club 25 | Other | Approved | Blood Donation | COMPLETED | NCT06138899 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| Club 25 | Other | Approved | Blood Donation | COMPLETED | NCT06138899 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| Club 25 | Other | Approved | Blood Donation | COMPLETED | NCT06138899 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| Club 25 | Other | Approved | Blood Donation | COMPLETED | NCT06138899 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| Club 25 | Other | Approved | Blood Donation | COMPLETED | NCT06138899 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| Club 25 | Other | Approved | Blood Donation | COMPLETED | NCT06138899 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| Club 25 | Other | Approved | Blood Donation | COMPLETED | NCT06138899 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Donidalorsen | Other | Phase PHASE2 | Hereditary Angioedema | COMPLETED | NCT04307381 |
| Stem Cell Transplantation | Other | Phase PHASE2 | Acute Myocardial Infarction | UNKNOWN | NCT00725738 |
| Stem Cell Transplantation | Other | Phase PHASE2 | Acute Myocardial Infarction | UNKNOWN | NCT00725738 |
| MIS | Other | Phase PHASE2 | Pancreatic Tubular Adenocarcinoma | UNKNOWN | NCT01021800 |
| MIS | Other | Phase PHASE2 | Pancreatic Tubular Adenocarcinoma | UNKNOWN | NCT01021800 |
| Observation | Other | Preclinical | Pancreatic Tubular Adenocarcinoma | UNKNOWN | NCT00947102 |
| Observation | Other | Preclinical | Pancreatic Tubular Adenocarcinoma | UNKNOWN | NCT00947102 |
| Observation | Other | Preclinical | Pancreatic Tubular Adenocarcinoma | UNKNOWN | NCT00947102 |
| Blood sampling | Other | Preclinical | Gene Expression | COMPLETED | NCT01052649 |
| Blood sampling | Other | Preclinical | Gene Expression | COMPLETED | NCT01052649 |
| Blood sampling | Other | Preclinical | Gene Expression | COMPLETED | NCT01052649 |
| Trans Sodium Crocetinate (TSC) | Other | Phase PHASE1 | High Grade Glioma | TERMINATED | NCT00826930 |
| Trans Sodium Crocetinate (TSC) | Other | Phase PHASE1 | High Grade Glioma | TERMINATED | NCT00826930 |
| Liberal RBC Transfusion | Other | Approved | Intensive Care | COMPLETED | NCT00944112 |
| Restrictive RBC Transfusion | Other | Approved | Intensive Care | COMPLETED | NCT00944112 |
| Liberal RBC Transfusion | Other | Approved | Intensive Care | COMPLETED | NCT00944112 |
| Restrictive RBC Transfusion | Other | Approved | Intensive Care | COMPLETED | NCT00944112 |
| Humulin, Humalog, Novolog | Other | Phase PHASE3 | Diabetes Mellitus | UNKNOWN | NCT01023165 |
| Humulin, Humalog, Novolog | Other | Phase PHASE3 | Diabetes Mellitus | UNKNOWN | NCT01023165 |
| 0.9% normal saline | Other | Phase PHASE1 | Intermittent Claudication | COMPLETED | NCT00725881 |
| Trans sodium crocetinate (TSC) | Other | Phase PHASE1 | Intermittent Claudication | COMPLETED | NCT00725881 |
| 0.9% normal saline | Other | Phase PHASE1 | Intermittent Claudication | COMPLETED | NCT00725881 |
| Trans sodium crocetinate (TSC) | Other | Phase PHASE1 | Intermittent Claudication | COMPLETED | NCT00725881 |
| Blood sampling | Other | Preclinical | Glioma | UNKNOWN | NCT01525459 |
| Glioma resection | Other | Preclinical | Glioma | UNKNOWN | NCT01525459 |
| Blood sampling | Other | Preclinical | Glioma | UNKNOWN | NCT01525459 |
| Glioma resection | Other | Preclinical | Glioma | UNKNOWN | NCT01525459 |
| ferrous gluconate | Other | Phase PHASE2 | Recovery of Hemoglobin and Iron Stores After Blood Donation | COMPLETED | NCT01555060 |
| ferrous gluconate | Other | Phase PHASE2 | Recovery of Hemoglobin and Iron Stores After Blood Donation | COMPLETED | NCT01555060 |
| FFP Infusion | Other | Phase PHASE3 | Blood Coagulation Disorders | WITHDRAWN | NCT00233246 |
| FFP Infusion | Other | Phase PHASE3 | Blood Coagulation Disorders | WITHDRAWN | NCT00233246 |
| SC therapy | Drug | Phase PHASE2 | Dilated Cardiomyopathy | COMPLETED | NCT00629018 |
| Bone Marrow Stimulation | Other | Phase PHASE2 | Dilated Cardiomyopathy | COMPLETED | NCT00629018 |
| CD34+ autologous stem cell transplantation | Other | Phase PHASE2 | Dilated Cardiomyopathy | COMPLETED | NCT00629018 |
| SC therapy | Drug | Phase PHASE2 | Dilated Cardiomyopathy | COMPLETED | NCT00629018 |
| Bone Marrow Stimulation | Other | Phase PHASE2 | Dilated Cardiomyopathy | COMPLETED | NCT00629018 |
| CD34+ autologous stem cell transplantation | Other | Phase PHASE2 | Dilated Cardiomyopathy | COMPLETED | NCT00629018 |
| Higher Dose Prophylactic Platelet Transfusions | Other | Phase PHASE3 | Thrombocytopenia | COMPLETED | NCT00128713 |
| Lower Dose Prophylactic Platelet Transfusions | Other | Phase PHASE3 | Thrombocytopenia | COMPLETED | NCT00128713 |
| Medium Dose Prophylactic Platelet Transfusions | Other | Phase PHASE3 | Thrombocytopenia | COMPLETED | NCT00128713 |
| Higher Dose Prophylactic Platelet Transfusions | Other | Phase PHASE3 | Thrombocytopenia | COMPLETED | NCT00128713 |
| Lower Dose Prophylactic Platelet Transfusions | Other | Phase PHASE3 | Thrombocytopenia | COMPLETED | NCT00128713 |
| Medium Dose Prophylactic Platelet Transfusions | Other | Phase PHASE3 | Thrombocytopenia | COMPLETED | NCT00128713 |
| Stress Reduction& Healthy living | Other | Approved | Diabetes | UNKNOWN | NCT02621008 |
| Stress Reduction& Healthy living | Other | Approved | Diabetes | UNKNOWN | NCT02621008 |
| Donidalorsen | Other | Phase PHASE2 | Hereditary Angioedema | COMPLETED | NCT04307381 |
| Donidalorsen | Other | Phase PHASE2 | Hereditary Angioedema | COMPLETED | NCT04307381 |
| Donidalorsen | Other | Phase PHASE2 | Hereditary Angioedema | COMPLETED | NCT04307381 |
| Donidalorsen | Other | Phase PHASE2 | Hereditary Angioedema | COMPLETED | NCT04307381 |
| Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog) | Drug | Phase PHASE2 | Hypoglycemia | WITHDRAWN | NCT01029639 |
| Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog) | Drug | Phase PHASE2 | Hypoglycemia | WITHDRAWN | NCT01029639 |
| Effects of Pulsatile IV Insulin on Diabetic Retinopathy | Other | Phase PHASE2 | Diabetes Mellitus, With Complications | TERMINATED | NCT00287651 |
| Pulsatile IV Insulin | Other | Phase PHASE2 | Diabetes Mellitus, With Complications | TERMINATED | NCT00287651 |
| Effects of Pulsatile IV Insulin on Diabetic Retinopathy | Other | Phase PHASE2 | Diabetes Mellitus, With Complications | TERMINATED | NCT00287651 |
| Pulsatile IV Insulin | Other | Phase PHASE2 | Diabetes Mellitus, With Complications | TERMINATED | NCT00287651 |
| Pulsatile IV insulin delivery (humalog, humulin, novolog) | Other | Phase PHASE2 | Diabetic Neuropathy | WITHDRAWN | NCT00228904 |
| Placebo | Other | Phase PHASE2 | Diabetic Neuropathy | WITHDRAWN | NCT00228904 |
| Pulsatile IV insulin delivery (humalog, humulin, novolog) | Other | Phase PHASE2 | Diabetic Neuropathy | WITHDRAWN | NCT00228904 |
| Placebo | Other | Phase PHASE2 | Diabetic Neuropathy | WITHDRAWN | NCT00228904 |
| Effect of Pulsatile IV Insulin on diabetic neuropathy | Other | Phase PHASE2 | Diabetes Mellitus, With Complications | TERMINATED | NCT00228891 |
| Effect of Pulsatile IV insulin on diabetic neuropathy | Other | Phase PHASE2 | Diabetes Mellitus, With Complications | TERMINATED | NCT00228891 |
| Effect of Pulsatile IV Insulin on diabetic neuropathy | Other | Phase PHASE2 | Diabetes Mellitus, With Complications | TERMINATED | NCT00228891 |
| Effect of Pulsatile IV insulin on diabetic neuropathy | Other | Phase PHASE2 | Diabetes Mellitus, With Complications | TERMINATED | NCT00228891 |
| Hydroxycarbamid | Other | Phase PHASE2 | Central Retinal Vein Occlusion, Non-Ischemic | UNKNOWN | NCT02957760 |
| Hydroxycarbamid | Other | Phase PHASE2 | Central Retinal Vein Occlusion, Non-Ischemic | UNKNOWN | NCT02957760 |
| Insuflon | Other | Approved | Venous Thromboembolism | COMPLETED | NCT00774748 |
| Insuflon | Other | Approved | Venous Thromboembolism | COMPLETED | NCT00774748 |
| Insuflon | Other | Approved | Venous Thromboembolism | COMPLETED | NCT00774748 |
| Trans Sodium Crocetinate (TSC) | Other | Phase PHASE1 | Glioblastoma | COMPLETED | NCT01465347 |
| Trans Sodium Crocetinate (TSC) | Other | Phase PHASE1 | Glioblastoma | COMPLETED | NCT01465347 |
| Trans Sodium Crocetinate (TSC) | Other | Phase PHASE1 | Glioblastoma | COMPLETED | NCT01465347 |
| Convalescent Plasma | Other | Phase PHASE2 | Hemorrhagic Fever, Ebola | COMPLETED | NCT02342171 |
| Convalescent Plasma | Other | Phase PHASE2 | Hemorrhagic Fever, Ebola | COMPLETED | NCT02342171 |
| Immunoglobulin Therapy | Drug | Preclinical | Primary Immune Deficiency Disorder | TERMINATED | NCT01883921 |
| Immunoglobulin Therapy | Drug | Preclinical | Primary Immune Deficiency Disorder | TERMINATED | NCT01883921 |
| Darbepoetin Alfa | Other | Phase PHASE2 | Erythroblastosis, Fetal | UNKNOWN | NCT03104426 |
| Darbepoetin Alfa | Other | Phase PHASE2 | Erythroblastosis, Fetal | UNKNOWN | NCT03104426 |
| Normale Saline Solution | Other | Phase PHASE3 | Shock Hemorrhagic | COMPLETED | NCT02736812 |
| French Lyophilized Plasma | Other | Phase PHASE3 | Shock Hemorrhagic | COMPLETED | NCT02736812 |
| Normale Saline Solution | Other | Phase PHASE3 | Shock Hemorrhagic | COMPLETED | NCT02736812 |
| French Lyophilized Plasma | Other | Phase PHASE3 | Shock Hemorrhagic | COMPLETED | NCT02736812 |
| Sample collection | Other | Preclinical | Hepatitis E | COMPLETED | NCT03601221 |
| Sample collection | Other | Preclinical | Hepatitis E | COMPLETED | NCT03601221 |
| Sample collection | Other | Preclinical | Hepatitis E | COMPLETED | NCT03601221 |
| convalescent plasma | Other | Phase PHASE1 | COVID-19 | UNKNOWN | NCT04356482 |
| convalescent plasma | Other | Phase PHASE1 | COVID-19 | UNKNOWN | NCT04356482 |
| Intravenous Immunoglobulin | Other | Preclinical | Chronic Inflammatory Demyelinating Polyneuropathy | COMPLETED | NCT02414490 |
| Intravenous Immunoglobulin | Other | Preclinical | Chronic Inflammatory Demyelinating Polyneuropathy | COMPLETED | NCT02414490 |
| Cognitive testing (Bayley III, WPPSI III and WISC V) | Other | Preclinical | Fetal and Neonatal Alloimmune Thrombocytopenia | UNKNOWN | NCT04529382 |
| Cognitive testing (Bayley III, WPPSI III and WISC V) | Other | Preclinical | Fetal and Neonatal Alloimmune Thrombocytopenia | UNKNOWN | NCT04529382 |
| Clinical data collection. | Other | Preclinical | Fetal and Neonatal Alloimmune Thrombocytopenia | COMPLETED | NCT04067375 |
| Clinical data collection. | Other | Preclinical | Fetal and Neonatal Alloimmune Thrombocytopenia | COMPLETED | NCT04067375 |
| Clinical data collection. | Other | Preclinical | Fetal and Neonatal Alloimmune Thrombocytopenia | COMPLETED | NCT04067375 |
| Blood transfusion | Other | Phase PHASE3 | Transfusion | COMPLETED | NCT01638416 |
| Blood transfusion | Other | Phase PHASE3 | Transfusion | COMPLETED | NCT01638416 |
| Blood transfusion | Other | Phase PHASE3 | Transfusion | COMPLETED | NCT01638416 |
| COVID Convalescent Plasma | Other | Approved | Covid19 | COMPLETED | NCT04542941 |
| COVID Convalescent Plasma | Other | Approved | Covid19 | COMPLETED | NCT04542941 |
| Extra DCE-CT scan | Other | Approved | Cancer, Lung | UNKNOWN | NCT04708483 |
| Extra DCE-CT scan | Other | Approved | Cancer, Lung | UNKNOWN | NCT04708483 |
| Olaparib | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06909825 |
| FPI-2265 | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06909825 |
| Olaparib | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06909825 |
| FPI-2265 | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06909825 |
| Olaparib | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06909825 |
| FPI-2265 | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06909825 |
| Nivolumab | Other | Phase PHASE1 | Malignant Pleural Effusion | TERMINATED | NCT03597009 |
| Talimogene laherparepvec (TVEC) | Other | Phase PHASE1 | Malignant Pleural Effusion | TERMINATED | NCT03597009 |
| Lactose monohydrate | Other | Phase PHASE2 | Acute Hepatitis A | TERMINATED | NCT00755950 |
| Silymarin | Other | Phase PHASE2 | Acute Hepatitis A | TERMINATED | NCT00755950 |
| Lactose monohydrate | Other | Phase PHASE2 | Acute Hepatitis A | TERMINATED | NCT00755950 |
| Silymarin | Other | Phase PHASE2 | Acute Hepatitis A | TERMINATED | NCT00755950 |
| Placebo | Other | Phase PHASE2 | Stroke, Acute | TERMINATED | NCT03763929 |
| Trans-Sodium Crocetinate | Other | Phase PHASE2 | Stroke, Acute | TERMINATED | NCT03763929 |
| Placebo | Other | Phase PHASE2 | Stroke, Acute | TERMINATED | NCT03763929 |
| Trans-Sodium Crocetinate | Other | Phase PHASE2 | Stroke, Acute | TERMINATED | NCT03763929 |
| Placebo | Other | Phase PHASE2 | Stroke, Acute | TERMINATED | NCT03763929 |
| Trans-Sodium Crocetinate | Other | Phase PHASE2 | Stroke, Acute | TERMINATED | NCT03763929 |
| Standard of Care (SOC) | Other | Phase PHASE3 | Glioblastoma | TERMINATED | NCT03393000 |
| Trans Sodium Crocetinate plus SOC | Other | Phase PHASE3 | Glioblastoma | TERMINATED | NCT03393000 |
| Standard of Care (SOC) | Other | Phase PHASE3 | Glioblastoma | TERMINATED | NCT03393000 |
| Trans Sodium Crocetinate plus SOC | Other | Phase PHASE3 | Glioblastoma | TERMINATED | NCT03393000 |
| Standard of Care (SOC) | Other | Phase PHASE3 | Glioblastoma | TERMINATED | NCT03393000 |
| Trans Sodium Crocetinate plus SOC | Other | Phase PHASE3 | Glioblastoma | TERMINATED | NCT03393000 |
| suspected of COVID-19 infection | Other | Preclinical | Covid19 | WITHDRAWN | NCT04615208 |
| suspected of COVID-19 infection | Other | Preclinical | Covid19 | WITHDRAWN | NCT04615208 |
| Lifestyle Intervention | Other | Approved | Sleep Disorder | COMPLETED | NCT03984058 |
| Lifestyle Intervention | Other | Approved | Sleep Disorder | COMPLETED | NCT03984058 |
| Convalescent/Vaccine-boosted Plasma (CP/PVP) | Other | Phase PHASE2 | SARS-CoV-2 Infection | UNKNOWN | NCT05200754 |
| Convalescent/Vaccine-boosted Plasma (CP/PVP) | Other | Phase PHASE2 | SARS-CoV-2 Infection | UNKNOWN | NCT05200754 |
| Convalescent/Vaccine-boosted Plasma (CP/PVP) | Other | Phase PHASE2 | SARS-CoV-2 Infection | UNKNOWN | NCT05200754 |
| Trans Sodium Crocetinate | Other | Phase PHASE1 | Healthy Volunteers With Induced Hypoxia | COMPLETED | NCT05036980 |
| Trans Sodium Crocetinate | Other | Phase PHASE1 | Healthy Volunteers With Induced Hypoxia | COMPLETED | NCT05036980 |
| Trans Sodium Crocetinate | Other | Phase PHASE1 | Healthy Volunteers With Induced Hypoxia | COMPLETED | NCT05036980 |
| Normal saline | Other | Phase PHASE1 | SARS-CoV-2 (Covid19) | COMPLETED | NCT04573322 |
| Trans Sodium Crocetinate | Other | Phase PHASE1 | SARS-CoV-2 (Covid19) | COMPLETED | NCT04573322 |
| Normal saline | Other | Phase PHASE1 | SARS-CoV-2 (Covid19) | COMPLETED | NCT04573322 |
| Trans Sodium Crocetinate | Other | Phase PHASE1 | SARS-CoV-2 (Covid19) | COMPLETED | NCT04573322 |
| Normal saline | Other | Phase PHASE1 | SARS-CoV-2 (Covid19) | COMPLETED | NCT04573322 |
| Trans Sodium Crocetinate | Other | Phase PHASE1 | SARS-CoV-2 (Covid19) | COMPLETED | NCT04573322 |
| Normal saline | Other | Phase PHASE1 | SARS-CoV-2 (Covid19) | COMPLETED | NCT04573322 |
| Trans Sodium Crocetinate | Other | Phase PHASE1 | SARS-CoV-2 (Covid19) | COMPLETED | NCT04573322 |
| Pain Medicine | Other | Approved | Chronic Nonmalignant Pain | COMPLETED | NCT04096391 |
| Flowonix Prometra® II Programmable Infusion System | Other | Approved | Chronic Nonmalignant Pain | COMPLETED | NCT04096391 |
| Pain Medicine | Other | Approved | Chronic Nonmalignant Pain | COMPLETED | NCT04096391 |
| Flowonix Prometra® II Programmable Infusion System | Other | Approved | Chronic Nonmalignant Pain | COMPLETED | NCT04096391 |
| Pain Medicine | Other | Approved | Chronic Nonmalignant Pain | COMPLETED | NCT04096391 |
| Flowonix Prometra® II Programmable Infusion System | Other | Approved | Chronic Nonmalignant Pain | COMPLETED | NCT04096391 |
| Placebo | Other | Phase PHASE2 | Interstitial Lung Disease | TERMINATED | NCT05079126 |
| Trans Sodium Crocetinate | Other | Phase PHASE2 | Interstitial Lung Disease | TERMINATED | NCT05079126 |
| Placebo | Other | Phase PHASE2 | Interstitial Lung Disease | TERMINATED | NCT05079126 |
| Trans Sodium Crocetinate | Other | Phase PHASE2 | Interstitial Lung Disease | TERMINATED | NCT05079126 |
| Placebo | Other | Phase PHASE2 | Interstitial Lung Disease | TERMINATED | NCT05079126 |
| Trans Sodium Crocetinate | Other | Phase PHASE2 | Interstitial Lung Disease | TERMINATED | NCT05079126 |
| Transfusion | Other | Preclinical | Anemia, Sickle Cell | COMPLETED | NCT03397017 |
| Transfusion | Other | Preclinical | Anemia, Sickle Cell | COMPLETED | NCT03397017 |
| Placebo | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT04808622 |
| Trans-Sodium Crocetinate | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT04808622 |
| Placebo | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT04808622 |
| Trans-Sodium Crocetinate | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT04808622 |
| Placebo | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT04808622 |
| Trans-Sodium Crocetinate | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT04808622 |
| SkillFlix for Parents | Other | Approved | Autism Spectrum Disorder | UNKNOWN | NCT05958394 |
| SkillFlix for Parents | Other | Approved | Autism Spectrum Disorder | UNKNOWN | NCT05958394 |
| allogeneic mesenchymal stromal stem cells | Other | Phase PHASE1 | Xerostomia Following Radiotherapy | UNKNOWN | NCT06012604 |
| allogeneic mesenchymal stromal stem cells | Other | Phase PHASE1 | Xerostomia Following Radiotherapy | UNKNOWN | NCT06012604 |
| allogeneic mesenchymal stromal stem cells | Other | Phase PHASE1 | Xerostomia Following Radiotherapy | UNKNOWN | NCT06012604 |
| Placebo | Other | Approved | Iron Deficiency | COMPLETED | NCT02245321 |
| Letter - No Information Provided | Other | Approved | Iron Deficiency | COMPLETED | NCT02245321 |
| Letter Group- Information Provided | Other | Approved | Iron Deficiency | COMPLETED | NCT02245321 |
| Ferrous gluconate- 38 mg | Other | Approved | Iron Deficiency | COMPLETED | NCT02245321 |
| Ferrous gluconate- 19 mg | Other | Approved | Iron Deficiency | COMPLETED | NCT02245321 |
| Placebo | Other | Approved | Iron Deficiency | COMPLETED | NCT02245321 |
| Letter - No Information Provided | Other | Approved | Iron Deficiency | COMPLETED | NCT02245321 |
| Letter Group- Information Provided | Other | Approved | Iron Deficiency | COMPLETED | NCT02245321 |
| Ferrous gluconate- 38 mg | Other | Approved | Iron Deficiency | COMPLETED | NCT02245321 |
| Ferrous gluconate- 19 mg | Other | Approved | Iron Deficiency | COMPLETED | NCT02245321 |
| vofatamab | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT05363605 |
| [111In]-FPI-1967 | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT05363605 |
| [225Ac]-FPI-1966 | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT05363605 |
| vofatamab | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT05363605 |
| [111In]-FPI-1967 | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT05363605 |
| [225Ac]-FPI-1966 | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT05363605 |
| Questionnaire for former bleeding events | Other | Preclinical | Hematologic Neoplasms | RECRUITING | NCT03505086 |
| Blood withdrawal | Other | Preclinical | Hematologic Neoplasms | RECRUITING | NCT03505086 |
| Questionnaire for former bleeding events | Other | Preclinical | Hematologic Neoplasms | RECRUITING | NCT03505086 |
| Blood withdrawal | Other | Preclinical | Hematologic Neoplasms | RECRUITING | NCT03505086 |
| Swab sample collection | Other | Preclinical | Preterm Birth | UNKNOWN | NCT06281262 |
| Peripheral blood collection | Other | Preclinical | Preterm Birth | UNKNOWN | NCT06281262 |
| Swab sample collection | Other | Preclinical | Preterm Birth | UNKNOWN | NCT06281262 |
| Peripheral blood collection | Other | Preclinical | Preterm Birth | UNKNOWN | NCT06281262 |
| Swab sample collection | Other | Preclinical | Preterm Birth | UNKNOWN | NCT06281262 |
| Peripheral blood collection | Other | Preclinical | Preterm Birth | UNKNOWN | NCT06281262 |
| dental prothesis | Other | Preclinical | Dental Prosthesis | UNKNOWN | NCT05130996 |
| dental prothesis | Other | Preclinical | Dental Prosthesis | UNKNOWN | NCT05130996 |
| dental prothesis | Other | Preclinical | Dental Prosthesis | UNKNOWN | NCT05130996 |
| Blinatumomab | Other | Phase PHASE2 | Lymphoblastic Leukemia, Acute, Adult | COMPLETED | NCT04554485 |
| Blinatumomab | Other | Phase PHASE2 | Lymphoblastic Leukemia, Acute, Adult | COMPLETED | NCT04554485 |
| General Health App | Other | Approved | HIV/AIDS | COMPLETED | NCT03897049 |
| Trans Women Connected | Other | Approved | HIV/AIDS | COMPLETED | NCT03897049 |
| General Health App | Other | Approved | HIV/AIDS | COMPLETED | NCT03897049 |
| Trans Women Connected | Other | Approved | HIV/AIDS | COMPLETED | NCT03897049 |
| COMET measurement system | Other | Preclinical | Mitochondrial Oxygenation Measurement | COMPLETED | NCT04626661 |
| COMET measurement system | Other | Preclinical | Mitochondrial Oxygenation Measurement | COMPLETED | NCT04626661 |
| Sui App (SRK) | Other | Approved | Quality of Life | COMPLETED | NCT05651737 |
| Sui App (SRK) | Other | Approved | Quality of Life | COMPLETED | NCT05651737 |
| Sui App (SRK) | Other | Approved | Quality of Life | COMPLETED | NCT05651737 |
| Protoporphyrin IX - Triplet State Lifetime Technique | Other | Preclinical | Sepsis | COMPLETED | NCT03842722 |
| Protoporphyrin IX - Triplet State Lifetime Technique | Other | Preclinical | Sepsis | COMPLETED | NCT03842722 |
| Convalescent COVID 19 Plasma | Other | Phase EARLY_PHASE1 | COVID 19 | COMPLETED | NCT04516954 |
| Convalescent COVID 19 Plasma | Other | Phase EARLY_PHASE1 | COVID 19 | COMPLETED | NCT04516954 |
| Wait-list | Other | Approved | Bereavement | COMPLETED | NCT06246708 |
| Self-help app with information for grieving Syrian Refugees | Other | Approved | Bereavement | COMPLETED | NCT06246708 |
| Wait-list | Other | Approved | Bereavement | COMPLETED | NCT06246708 |
| Self-help app with information for grieving Syrian Refugees | Other | Approved | Bereavement | COMPLETED | NCT06246708 |
| Ponatinib 15 MG Oral Tablet | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia, Adult | TERMINATED | NCT04554459 |
| Ponatinib 15 MG Oral Tablet | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia, Adult | TERMINATED | NCT04554459 |
| Immune checkpoint inhibitor | Other | Approved | Metastatic Melanoma | RECRUITING | NCT05878977 |
| Immune checkpoint inhibitor | Other | Approved | Metastatic Melanoma | RECRUITING | NCT05878977 |
| Immune checkpoint inhibitor | Other | Approved | Metastatic Melanoma | RECRUITING | NCT05878977 |
| General Health Materials Website | Other | Approved | HIV/AIDS and Infections | COMPLETED | NCT04135443 |
| 3T Tune in! Turn on! Turn up! | Other | Approved | HIV/AIDS and Infections | COMPLETED | NCT04135443 |
| General Health Materials Website | Other | Approved | HIV/AIDS and Infections | COMPLETED | NCT04135443 |
| 3T Tune in! Turn on! Turn up! | Other | Approved | HIV/AIDS and Infections | COMPLETED | NCT04135443 |
| Quantitative Indocyanine Green Fluorescence Angiography | Other | Preclinical | Colorectal Cancer | COMPLETED | NCT05153954 |
| Quantitative Indocyanine Green Fluorescence Angiography | Other | Preclinical | Colorectal Cancer | COMPLETED | NCT05153954 |
| Quantitative Indocyanine Green Fluorescence Angiography | Other | Preclinical | Colorectal Cancer | COMPLETED | NCT05153954 |
| Knee aspiration | Other | Approved | Osteoarthritis, Knee | COMPLETED | NCT06078059 |
| Knee aspiration + UCB-MSCs | Other | Approved | Osteoarthritis, Knee | COMPLETED | NCT06078059 |
| Knee aspiration | Other | Approved | Osteoarthritis, Knee | COMPLETED | NCT06078059 |
| Knee aspiration + UCB-MSCs | Other | Approved | Osteoarthritis, Knee | COMPLETED | NCT06078059 |
| Neuro-NAC XS | Other | Approved | Pharmacokinetics | COMPLETED | NCT06252519 |
| Neuro-NAC | Other | Approved | Pharmacokinetics | COMPLETED | NCT06252519 |
| NAC | Other | Approved | Pharmacokinetics | COMPLETED | NCT06252519 |
| Neuro-NAC XS | Other | Approved | Pharmacokinetics | COMPLETED | NCT06252519 |
| Neuro-NAC | Other | Approved | Pharmacokinetics | COMPLETED | NCT06252519 |
| NAC | Other | Approved | Pharmacokinetics | COMPLETED | NCT06252519 |
| DBS | Other | Approved | Severe Permanent Uni or Bilateral Non-pulsatile Tinnitus | RECRUITING | NCT04296097 |
| DBS | Other | Approved | Severe Permanent Uni or Bilateral Non-pulsatile Tinnitus | RECRUITING | NCT04296097 |
| Autologous CAR19 T lymphocytes | Other | Phase PHASE1 | Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia | RECRUITING | NCT05054257 |
| Autologous CAR19 T lymphocytes | Other | Phase PHASE1 | Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia | RECRUITING | NCT05054257 |
| Bleeding assessment tool | Other | Preclinical | Perioperative Hemorrhage | COMPLETED | NCT04993170 |
| Bleeding assessment tool | Other | Preclinical | Perioperative Hemorrhage | COMPLETED | NCT04993170 |
| Non applicable, is a patient registry | Other | Preclinical | Hemoglobinopathies | COMPLETED | NCT06831799 |
| Non applicable, is a patient registry | Other | Preclinical | Hemoglobinopathies | COMPLETED | NCT06831799 |
| SE3 Game | Other | Phase EARLY_PHASE1 | Effect of Game in Increasing Environmental Health Literacy | COMPLETED | NCT05875467 |
| SE3 Game | Other | Phase EARLY_PHASE1 | Effect of Game in Increasing Environmental Health Literacy | COMPLETED | NCT05875467 |
| Ticagrelor | Other | Phase PHASE4 | Acute Myocardial Infarction | COMPLETED | NCT03551964 |
| Cangrelor | Other | Phase PHASE4 | Acute Myocardial Infarction | COMPLETED | NCT03551964 |
| Ticagrelor | Other | Phase PHASE4 | Acute Myocardial Infarction | COMPLETED | NCT03551964 |
| Cangrelor | Other | Phase PHASE4 | Acute Myocardial Infarction | COMPLETED | NCT03551964 |
| Green tea flavoured, placebo drink | Other | Approved | The Focus of the Study is Healthy Volunteers | COMPLETED | NCT06224569 |
| Green tea flavoured, caffeine-only drink | Other | Approved | The Focus of the Study is Healthy Volunteers | COMPLETED | NCT06224569 |
| Green tea flavoured, tea drink | Other | Approved | The Focus of the Study is Healthy Volunteers | COMPLETED | NCT06224569 |
| Black tea flavoured, placebo drink | Other | Approved | The Focus of the Study is Healthy Volunteers | COMPLETED | NCT06224569 |
| Black tea flavoured, caffeine-only drink | Other | Approved | The Focus of the Study is Healthy Volunteers | COMPLETED | NCT06224569 |
| Black tea flavoured, tea drink | Other | Approved | The Focus of the Study is Healthy Volunteers | COMPLETED | NCT06224569 |
| Green tea flavoured, placebo drink | Other | Approved | The Focus of the Study is Healthy Volunteers | COMPLETED | NCT06224569 |
| Green tea flavoured, caffeine-only drink | Other | Approved | The Focus of the Study is Healthy Volunteers | COMPLETED | NCT06224569 |
| Green tea flavoured, tea drink | Other | Approved | The Focus of the Study is Healthy Volunteers | COMPLETED | NCT06224569 |
| Black tea flavoured, placebo drink | Other | Approved | The Focus of the Study is Healthy Volunteers | COMPLETED | NCT06224569 |
| Black tea flavoured, caffeine-only drink | Other | Approved | The Focus of the Study is Healthy Volunteers | COMPLETED | NCT06224569 |
| Black tea flavoured, tea drink | Other | Approved | The Focus of the Study is Healthy Volunteers | COMPLETED | NCT06224569 |
| Apheresis donation | Other | Approved | Blood Donation | RECRUITING | NCT06809010 |
| Whole blood donation | Other | Approved | Blood Donation | RECRUITING | NCT06809010 |
| Apheresis donation | Other | Approved | Blood Donation | RECRUITING | NCT06809010 |
| Whole blood donation | Other | Approved | Blood Donation | RECRUITING | NCT06809010 |
| In-person facilitator training for Making Proud Choices | Other | Approved | Teacher Training | COMPLETED | NCT04227236 |
| E-based virtual facilitator training for Making Proud Choices | Other | Approved | Teacher Training | COMPLETED | NCT04227236 |
| In-person facilitator training for Making Proud Choices | Other | Approved | Teacher Training | COMPLETED | NCT04227236 |
| E-based virtual facilitator training for Making Proud Choices | Other | Approved | Teacher Training | COMPLETED | NCT04227236 |
| anti-CD19 CAR T-cells | Other | Phase PHASE1 | B-Cell Non Hodgkin Lymphoma | COMPLETED | NCT06027957 |
| anti-CD19 CAR T-cells | Other | Phase PHASE1 | B-Cell Non Hodgkin Lymphoma | COMPLETED | NCT06027957 |
| [211At]NaAt | Other | Phase PHASE1 | DTC - Differentiated Thyroid Cancer | RECRUITING | NCT07287748 |
| [211At]NaAt | Other | Phase PHASE1 | DTC - Differentiated Thyroid Cancer | RECRUITING | NCT07287748 |
| [211At]NaAt | Other | Phase PHASE1 | DTC - Differentiated Thyroid Cancer | RECRUITING | NCT07287748 |
| [225Ac]-FPI-1434 Injection single-dose | Other | Phase PHASE1 | Advanced Solid Tumours | TERMINATED | NCT03746431 |
| FPI-1175 Infusion | Other | Phase PHASE1 | Advanced Solid Tumours | TERMINATED | NCT03746431 |
| [225Ac]-FPI-1434 Injection multi-dose | Other | Phase PHASE1 | Advanced Solid Tumours | TERMINATED | NCT03746431 |
| [111In]-FPI-1547 Injection | Other | Phase PHASE1 | Advanced Solid Tumours | TERMINATED | NCT03746431 |
| [225Ac]-FPI-1434 Injection single-dose | Other | Phase PHASE1 | Advanced Solid Tumours | TERMINATED | NCT03746431 |
| FPI-1175 Infusion | Other | Phase PHASE1 | Advanced Solid Tumours | TERMINATED | NCT03746431 |
| [225Ac]-FPI-1434 Injection multi-dose | Other | Phase PHASE1 | Advanced Solid Tumours | TERMINATED | NCT03746431 |
| [111In]-FPI-1547 Injection | Other | Phase PHASE1 | Advanced Solid Tumours | TERMINATED | NCT03746431 |
| Autologous CAR123 T lymphocytes | Other | Phase EARLY_PHASE1 | Leukemia, Myeloid, Acute(AML) | RECRUITING | NCT06765876 |
| Autologous CAR123 T lymphocytes | Other | Phase EARLY_PHASE1 | Leukemia, Myeloid, Acute(AML) | RECRUITING | NCT06765876 |
| CPAP | Other | Approved | Ischemic Stroke | ACTIVE_NOT_RECRUITING | NCT03812653 |
| CPAP | Other | Approved | Ischemic Stroke | ACTIVE_NOT_RECRUITING | NCT03812653 |
| CPAP | Other | Approved | Ischemic Stroke | ACTIVE_NOT_RECRUITING | NCT03812653 |
| FPI-2265 | Other | Phase PHASE2 | Metastatic Castration Resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05219500 |
| FPI-2265 | Other | Phase PHASE2 | Metastatic Castration Resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05219500 |
| Club 25 | Other | Approved | Blood Donation | ACTIVE_NOT_RECRUITING | NCT06138899 |
| Club 25 | Other | Approved | Blood Donation | ACTIVE_NOT_RECRUITING | NCT06138899 |
| Olaparib | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06909825 |
| FPI-2265 | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06909825 |
| FPI-2265 | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06402331 |
| Proton Total Marrow Irradiation | Other | Phase PHASE1 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07532824 |
| Proton Total Marrow Irradiation | Other | Phase PHASE1 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07532824 |
| Olaparib | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06909825 |
| FPI-2265 | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06909825 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| AZD9150 | Other | Phase PHASE1 | Advanced Adult Hepatocellular Carcinoma | COMPLETED | NCT01839604 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | COMPLETED | NCT02519036 |
| ISIS 443139 120 mg | Other | Phase PHASE1 | Huntington's Disease | COMPLETED | NCT02519036 |
| ISIS 443139 90 mg | Other | Phase PHASE1 | Huntington's Disease | COMPLETED | NCT02519036 |
| ISIS 443139 60 mg | Other | Phase PHASE1 | Huntington's Disease | COMPLETED | NCT02519036 |
| ISIS 443139 30 mg | Other | Phase PHASE1 | Huntington's Disease | COMPLETED | NCT02519036 |
| ISIS 443139 10 mg | Other | Phase PHASE1 | Huntington's Disease | COMPLETED | NCT02519036 |
| Placebo | Other | Phase PHASE2 | Hepatic Steatosis | COMPLETED | NCT03334214 |
| IONIS DGAT2Rx | Other | Phase PHASE2 | Hepatic Steatosis | COMPLETED | NCT03334214 |
| Placebo | Other | Phase PHASE2 | Familial Partial Lipodystrophy | TERMINATED | NCT02527343 |
| volanesorsen | Other | Phase PHASE2 | Familial Partial Lipodystrophy | TERMINATED | NCT02527343 |
| Placebo | Other | Phase PHASE2 | Chronic Bronchitis | TERMINATED | NCT04441788 |
| ION-827359 | Other | Phase PHASE2 | Chronic Bronchitis | TERMINATED | NCT04441788 |
| ION537 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT04659096 |
| ISIS 333611 | Other | Phase PHASE1 | Familial Amyotrophic Lateral Sclerosis | COMPLETED | NCT01041222 |
| ISIS CRP Rx or Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT01414101 |
| Enoxaparin | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT01713361 |
| ISIS-FXIRx Dose #3 | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT01713361 |
| ISIS-FXIRx Dose #2 | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT01713361 |
| daily OAD (metformin and/or sulfonylurea) | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01918865 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01918865 |
| ISIS-PTP1BRx | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01918865 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01968265 |
| ISIS-GCCRRx | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01968265 |
| Placebo | Other | Phase PHASE2 | Paroxysmal Atrial Fibrillation | COMPLETED | NCT01710852 |
| ISIS CRP Rx | Other | Phase PHASE2 | Paroxysmal Atrial Fibrillation | COMPLETED | NCT01710852 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01885260 |
| ISIS-GCGRRx - Dose Level 2 | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01885260 |
| ISIS-GCGRRx - Dose Level 1 | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01885260 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01414881 |
| mipomersen | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01414881 |
| placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01299298 |
| mipomersen | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01299298 |
| mipomersen sodium; warfarin sodium | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01133366 |
| warfarin sodium | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01133366 |
| placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01090661 |
| moxifloxacin hydrochloride (Avelox®) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01090661 |
| mipomersen sodium | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01090661 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01061814 |
| mipomersen | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01061814 |
| Isis 420915/GSK 299872 | Other | Phase PHASE2 | Amyloidosis | WITHDRAWN | NCT02627820 |
| Placebo | Other | Phase PHASE2 | End-stage Renal Disease (ESRD) | COMPLETED | NCT02553889 |
| ISIS 416858 | Other | Phase PHASE2 | End-stage Renal Disease (ESRD) | COMPLETED | NCT02553889 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes | COMPLETED | NCT02824003 |
| ISIS-GCGRRx | Other | Phase PHASE2 | Type 2 Diabetes | COMPLETED | NCT02824003 |
| Placebo Comparator | Other | Phase PHASE1 | Elevated Triglycerides (TG) | COMPLETED | NCT02900027 |
| APOC-III-L-Rx | Other | Phase PHASE1 | Elevated Triglycerides (TG) | COMPLETED | NCT02900027 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes | COMPLETED | NCT02583919 |
| ISIS-GCGRRx- Dose Level 2 | Other | Phase PHASE2 | Type 2 Diabetes | COMPLETED | NCT02583919 |
| ISIS-GCGRRx- Dose Level 1 | Other | Phase PHASE2 | Type 2 Diabetes | COMPLETED | NCT02583919 |
| Placebo | Other | Phase PHASE2 | Obesity | COMPLETED | NCT02476019 |
| ISIS-FGFR4RX | Other | Phase PHASE2 | Obesity | COMPLETED | NCT02476019 |
| IONIS-STAT3Rx | Other | Phase PHASE1 | Advanced Cancers | COMPLETED | NCT01563302 |
| Carboplatin | Other | Phase PHASE1 | Non-small Cell Lung Cancer | COMPLETED | NCT01234038 |
| Paclitaxel | Other | Phase PHASE1 | Non-small Cell Lung Cancer | COMPLETED | NCT01234038 |
| ISIS EIF4E Rx | Other | Phase PHASE1 | Non-small Cell Lung Cancer | COMPLETED | NCT01234038 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03101878 |
| Ionis AGT-LRx | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03101878 |
| AKCEA-ANGPTL3-LRX | Other | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | WITHDRAWN | NCT03455777 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE1 | Elevated Lipoprotein(a) | COMPLETED | NCT02414594 |
| IONIS-APO(a)-LRx | Other | Phase PHASE1 | Elevated Lipoprotein(a) | COMPLETED | NCT02414594 |
| Placebo | Other | Phase PHASE1 | Thalassemia | COMPLETED | NCT03165864 |
| IONIS TMPRSS6-Lrx | Other | Phase PHASE1 | Thalassemia | COMPLETED | NCT03165864 |
| ISIS 681257 | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT03506854 |
| Placebo | Other | Phase PHASE2 | FAP | COMPLETED | NCT01737398 |
| Inotersen | Other | Phase PHASE2 | FAP | COMPLETED | NCT01737398 |
| Inotersen | Other | Preclinical | Amyloidosis, Hereditary | APPROVED_FOR_MARKETING | NCT03400098 |
| Placebo (sterline saline 0.9%) | Other | Phase PHASE2 | Geographic Atrophy | WITHDRAWN | NCT03446144 |
| IONIS-FB-Lrx | Other | Phase PHASE2 | Geographic Atrophy | WITHDRAWN | NCT03446144 |
| Placebo | Other | Phase PHASE2 | Elevated Lipoprotein(a) | COMPLETED | NCT02160899 |
| ISIS-APO(a)Rx | Other | Phase PHASE2 | Elevated Lipoprotein(a) | COMPLETED | NCT02160899 |
| Placebo | Other | Phase PHASE2 | Chronic Migraine | COMPLETED | NCT03108469 |
| IONIS-PKKRx (ISIS 546254) | Other | Phase PHASE2 | Chronic Migraine | COMPLETED | NCT03108469 |
| Placebo | Other | Phase PHASE2 | Elevated Lipoprotein(a) | COMPLETED | NCT03070782 |
| ISIS 681257 | Other | Phase PHASE2 | Elevated Lipoprotein(a) | COMPLETED | NCT03070782 |
| Placebo | Other | Phase PHASE1 | Hypertriglyceridemia | COMPLETED | NCT02709850 |
| IONIS ANGPTL3-LRx | Other | Phase PHASE1 | Hypertriglyceridemia | COMPLETED | NCT02709850 |
| AKCEA-ANGPTL3-LRx | Other | Phase PHASE2 | Familial Chylomicronemia Syndrome | COMPLETED | NCT03360747 |
| ISIS 703802 20 mg | Other | Phase PHASE2 | NAFLD | COMPLETED | NCT03371355 |
| ISIS 703802 80 mg | Other | Phase PHASE2 | NAFLD | COMPLETED | NCT03371355 |
| ISIS 703802 40 mg | Other | Phase PHASE2 | NAFLD | COMPLETED | NCT03371355 |
| Placebo | Other | Phase PHASE2 | NAFLD | COMPLETED | NCT03371355 |
| Placebo | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT03647228 |
| IONIS-ENaCRx | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT03647228 |
| AKCEA-ANGPTL3-LRx | Other | Phase PHASE2 | Familial Partial Lipodystrophy | COMPLETED | NCT03514420 |
| Placebo | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT02981602 |
| IONIS-HBVRx | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT02981602 |
| Volanesorsen | Other | Phase PHASE3 | Familial Chylomicronemia Syndrome | COMPLETED | NCT02658175 |
| Placebo | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03582462 |
| IONIS FXI-LRx | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03582462 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes | TERMINATED | NCT01647308 |
| ISIS-APOCIIIRX | Other | Phase PHASE2 | Type 2 Diabetes | TERMINATED | NCT01647308 |
| Placebo | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT01529424 |
| ISIS apoC-III Rx | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT01529424 |
| Placebo | Other | Phase PHASE1 | Abnormalities, Cardiovascular | COMPLETED | NCT02910635 |
| Moxifloxacin | Other | Phase PHASE1 | Abnormalities, Cardiovascular | COMPLETED | NCT02910635 |
| Volanesorsen | Other | Phase PHASE1 | Abnormalities, Cardiovascular | COMPLETED | NCT02910635 |
| Placebo | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT04302064 |
| Eplontersen | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT04302064 |
| Placebo | Other | Phase PHASE3 | Hypertriglyceridemia | COMPLETED | NCT02300233 |
| Volanesorsen | Other | Phase PHASE3 | Hypertriglyceridemia | COMPLETED | NCT02300233 |
| Placebo | Other | Phase PHASE3 | Familial Chylomicronemia Syndrome | COMPLETED | NCT02211209 |
| Volanesorsen | Other | Phase PHASE3 | Familial Chylomicronemia Syndrome | COMPLETED | NCT02211209 |
| Pelacarsen | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05337878 |
| Placebo | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05337878 |
| Donidalorsen | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03263507 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03263507 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04731623 |
| ION904 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04731623 |
| Normal Saline | Other | Phase PHASE2 | Covid19 | COMPLETED | NCT04549922 |
| ISIS 721744 | Other | Phase PHASE2 | Covid19 | COMPLETED | NCT04549922 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04934891 |
| ION547 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04934891 |
| Placebo | Other | Phase PHASE2 | Acromegaly | COMPLETED | NCT03548415 |
| IONIS-GHR-LRx | Other | Phase PHASE2 | Acromegaly | COMPLETED | NCT03548415 |
| Placebo | Other | Phase PHASE1 | Myotonic Dystrophy Type 1 | COMPLETED | NCT02312011 |
| IONIS-DMPKRx | Other | Phase PHASE1 | Myotonic Dystrophy Type 1 | COMPLETED | NCT02312011 |
| Vitamin A | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03728634 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03728634 |
| ION-682884 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03728634 |
| ISIS 757456 | Other | Phase PHASE2 | Mild Hypertension | COMPLETED | NCT03714776 |
| Placebo | Other | Phase PHASE2 | Mild Hypertension | COMPLETED | NCT03714776 |
| Placebo | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT03385239 |
| ISIS 678354 | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT03385239 |
| ISIS 757456 | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT04083222 |
| Placebo | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT04083222 |
| Placebo | Other | Phase PHASE2 | End-stage Renal Disease (ESRD) | COMPLETED | NCT03358030 |
| ISIS 416858 | Other | Phase PHASE2 | End-stage Renal Disease (ESRD) | COMPLETED | NCT03358030 |
| Somatostatin Receptor Ligand (SRL) | Other | Phase PHASE2 | Acromegaly | COMPLETED | NCT03967249 |
| IONIS GHR-LRx | Other | Phase PHASE2 | Acromegaly | COMPLETED | NCT03967249 |
| Placebo | Other | Phase PHASE2 | Hereditary Angioedema | COMPLETED | NCT04030598 |
| Donidalorsen | Other | Phase PHASE2 | Hereditary Angioedema | COMPLETED | NCT04030598 |
| Placebo | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT02623699 |
| Tofersen | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT02623699 |
| Placebo | Other | Phase PHASE2 | Chronic Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT04836182 |
| IONIS-AGT-LRx | Other | Phase PHASE2 | Chronic Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT04836182 |
| Docetaxel | Other | Phase PHASE1 | Castrate-Resistant Prostate Cancer | COMPLETED | NCT01234025 |
| Prednisone | Other | Phase PHASE1 | Castrate-Resistant Prostate Cancer | COMPLETED | NCT01234025 |
| ISIS EIF4E Rx | Other | Phase PHASE1 | Castrate-Resistant Prostate Cancer | COMPLETED | NCT01234025 |
| Inotersen | Other | Phase PHASE3 | FAP | COMPLETED | NCT02175004 |
| Placebo | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT05314439 |
| ION904 | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT05314439 |
| Olezarsen | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05579860 |
| GHR-LRX | Other | Phase PHASE2 | Acromegaly | COMPLETED | NCT04522180 |
| ION251 | Other | Phase PHASE1 | Relapsed Multiple Myeloma | COMPLETED | NCT04398485 |
| Placebo | Other | Phase PHASE2 | Steatohepatitis, Nonalcoholic | COMPLETED | NCT04932512 |
| ION224 | Other | Phase PHASE2 | Steatohepatitis, Nonalcoholic | COMPLETED | NCT04932512 |
| Eplontersen | Other | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloid Polyneuropathy | COMPLETED | NCT04136184 |
| Inotersen | Other | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloid Polyneuropathy | COMPLETED | NCT04136184 |
| Olezarsen | Other | Preclinical | Familial Chylomicronemia Syndrome | APPROVED_FOR_MARKETING | NCT06360237 |
| IONIS-FB-LRx | Other | Phase PHASE2 | Primary IgA Nephropathy | COMPLETED | NCT04014335 |
| 99m-technetium pyrophosphate scintigraphy | Other | Preclinical | Amyloidosis | TERMINATED | NCT05259072 |
| IONIS-AGT-LRx | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT04714320 |
| Placebo | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT04714320 |
| sapablursen | Other | Phase PHASE2 | Beta Thalassemia Intermedia | TERMINATED | NCT04059406 |
| Placebo | Other | Phase PHASE3 | Hereditary Angioedema | COMPLETED | NCT05139810 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema | COMPLETED | NCT05139810 |
| Placebo | Other | Phase PHASE3 | Familial Chylomicronemia Syndrome | COMPLETED | NCT04568434 |
| Olezarsen | Other | Phase PHASE3 | Familial Chylomicronemia Syndrome | COMPLETED | NCT04568434 |
| Placebo | Other | Phase PHASE2 | Macular Degeneration | COMPLETED | NCT03815825 |
| IONIS-FB-LRx | Other | Phase PHASE2 | Macular Degeneration | COMPLETED | NCT03815825 |
| Donidalorsen | Other | Phase PHASE2 | Hereditary Angioedema | COMPLETED | NCT04307381 |
| Placebo | Other | Phase PHASE1 | Mild Alzheimer's Disease | COMPLETED | NCT03186989 |
| IONIS MAPTRx | Other | Phase PHASE1 | Mild Alzheimer's Disease | COMPLETED | NCT03186989 |
| Donidalorsen | Other | Preclinical | Hereditary Angioedema | AVAILABLE | NCT06415448 |
| Placebo | Other | Phase PHASE3 | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | ACTIVE_NOT_RECRUITING | NCT04136171 |
| Eplontersen | Other | Phase PHASE3 | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | ACTIVE_NOT_RECRUITING | NCT04136171 |
| Tofersen | Other | Phase PHASE3 | ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation | COMPLETED | NCT03070119 |
| Placebo | Other | Phase PHASE1 | Parkinson's Disease | COMPLETED | NCT03976349 |
| BIIB094 | Other | Phase PHASE1 | Parkinson's Disease | COMPLETED | NCT03976349 |
| Eplontersen | Other | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloid Polyneuropathy | ACTIVE_NOT_RECRUITING | NCT05071300 |
| Placebo | Other | Phase PHASE3 | Severe Hypertriglyceridemia | COMPLETED | NCT05552326 |
| Olezarsen | Other | Phase PHASE3 | Severe Hypertriglyceridemia | COMPLETED | NCT05552326 |
| ION582 | Other | Phase PHASE1 | Angelman Syndrome | RECRUITING | NCT05127226 |
| Magnetic Resonance Imaging (MRI) | Other | Preclinical | Spinocerebellar Ataxia Type 2 | COMPLETED | NCT04288128 |
| Lumbar puncture | Other | Preclinical | Spinocerebellar Ataxia Type 2 | COMPLETED | NCT04288128 |
| Scintigraphy scan | Other | Preclinical | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) | ACTIVE_NOT_RECRUITING | NCT06073587 |
| Cardiac MRI | Other | Preclinical | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) | ACTIVE_NOT_RECRUITING | NCT06073574 |
| Olezarsen | Other | Phase PHASE3 | Severe Hypertriglyceridemia | ACTIVE_NOT_RECRUITING | NCT05681351 |
| ION356 | Other | Phase PHASE1 | Pelizaeus-Merzbacher Disease | RECRUITING | NCT06150716 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema | ACTIVE_NOT_RECRUITING | NCT05392114 |
| Olezarsen | Other | Phase PHASE3 | Familial Chylomicronemia Syndrome | ACTIVE_NOT_RECRUITING | NCT05185843 |
| Olezarsen | Other | Phase PHASE3 | Familial Chylomicronemia Syndrome | ACTIVE_NOT_RECRUITING | NCT05130450 |
| sapablursen | Other | Phase PHASE2 | Phlebotomy Dependent Polycythemia Vera | ACTIVE_NOT_RECRUITING | NCT05143957 |
| Placebo | Other | Phase PHASE3 | Hypertriglyceridemia | COMPLETED | NCT05610280 |
| Olezarsen | Other | Phase PHASE3 | Hypertriglyceridemia | COMPLETED | NCT05610280 |
| Placebo | Other | Phase PHASE3 | Severe Hypertriglyceridemia | COMPLETED | NCT05079919 |
| Olezarsen | Other | Phase PHASE3 | Severe Hypertriglyceridemia | COMPLETED | NCT05079919 |
| Placebo | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis | ACTIVE_NOT_RECRUITING | NCT04768972 |
| ION363 | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis | ACTIVE_NOT_RECRUITING | NCT04768972 |
| ION269 | Other | Phase PHASE1 | Alzheimer Disease | TERMINATED | NCT06673069 |
| Nerve conduction study | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | COMPLETED | NCT05311488 |
| In-vivo Meissner Corpuscle imaging | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | COMPLETED | NCT05311488 |
| neurofilament light chain | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | COMPLETED | NCT05311488 |
| zilganersen | Other | Preclinical | Alexander Disease | AVAILABLE | NCT07487389 |
| Sham procedure | Procedure | Phase PHASE1 | Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome | RECRUITING | NCT06430385 |
| ION440 | Other | Phase PHASE1 | Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome | RECRUITING | NCT06430385 |
| Placebo | Other | Phase PHASE3 | Alexander Disease | ACTIVE_NOT_RECRUITING | NCT04849741 |
| zilganersen | Other | Phase PHASE3 | Alexander Disease | ACTIVE_NOT_RECRUITING | NCT04849741 |
| Eplontersen | Other | Phase PHASE3 | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | ENROLLING_BY_INVITATION | NCT05667493 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| Placebo | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT05355402 |
| Olezarsen | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT05355402 |
| Placebo | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| ION717 | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| Placebo | Other | Phase PHASE1 | Multiple System Atrophy | RECRUITING | NCT04165486 |
| ION464 | Other | Phase PHASE1 | Multiple System Atrophy | RECRUITING | NCT04165486 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| Placebo | Other | Phase PHASE1 | Multiple System Atrophy | RECRUITING | NCT04165486 |
| ION464 | Other | Phase PHASE1 | Multiple System Atrophy | RECRUITING | NCT04165486 |
| Placebo | Other | Phase PHASE1 | Multiple System Atrophy | RECRUITING | NCT04165486 |
| ION464 | Other | Phase PHASE1 | Multiple System Atrophy | RECRUITING | NCT04165486 |
| Placebo | Other | Phase PHASE1 | Multiple System Atrophy | RECRUITING | NCT04165486 |
| ION464 | Other | Phase PHASE1 | Multiple System Atrophy | RECRUITING | NCT04165486 |
| Placebo | Other | Phase PHASE1 | Multiple System Atrophy | RECRUITING | NCT04165486 |
| ION464 | Other | Phase PHASE1 | Multiple System Atrophy | RECRUITING | NCT04165486 |
| Placebo | Other | Phase PHASE1 | Multiple System Atrophy | RECRUITING | NCT04165486 |
| ION464 | Other | Phase PHASE1 | Multiple System Atrophy | RECRUITING | NCT04165486 |
| Placebo | Other | Phase PHASE1 | Multiple System Atrophy | RECRUITING | NCT04165486 |
| ION464 | Other | Phase PHASE1 | Multiple System Atrophy | RECRUITING | NCT04165486 |
| Placebo | Other | Phase PHASE1 | Multiple System Atrophy | RECRUITING | NCT04165486 |
| ION464 | Other | Phase PHASE1 | Multiple System Atrophy | RECRUITING | NCT04165486 |
| Placebo | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| ION717 | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| ION717 | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| ION717 | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| ION717 | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| ION717 | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| ION717 | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| ION717 | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| ION717 | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| ION717 | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| ION717 | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT05355402 |
| Olezarsen | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT05355402 |
| Placebo | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| ION717 | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT05355402 |
| Olezarsen | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT05355402 |
| Placebo | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| ION717 | Other | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| Placebo | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION582 | Other | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| Placebo | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT05355402 |
| Olezarsen | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT05355402 |
| Placebo | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT05355402 |
| Olezarsen | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT05355402 |
| Placebo | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT05355402 |
| Olezarsen | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT05355402 |
| Placebo | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT05355402 |
| Olezarsen | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT05355402 |
| Placebo | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT05355402 |
| Olezarsen | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT05355402 |
| Placebo | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT05355402 |
| Olezarsen | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT05355402 |
| Placebo | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT05355402 |
| Olezarsen | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT05355402 |
| Placebo | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT05355402 |
| Olezarsen | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT05355402 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| ION337 | Other | Phase PHASE1 | Dravet Syndrome | RECRUITING | NCT07531745 |
| Eplontersen | Other | Phase PHASE3 | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | ENROLLING_BY_INVITATION | NCT05667493 |
| Donidalorsen | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| [225Ac]-FPI-1434 Injection single-dose | DRUG | Phase PHASE1 | Advanced Solid Tumours | TERMINATED | NCT03746431 |
| FPI-1175 Infusion | BIOLOGICAL | Phase PHASE1 | Advanced Solid Tumours | TERMINATED | NCT03746431 |
| [225Ac]-FPI-1434 Injection multi-dose | DRUG | Phase PHASE1 | Advanced Solid Tumours | TERMINATED | NCT03746431 |
| [111In]-FPI-1547 Injection | DRUG | Phase PHASE1 | Advanced Solid Tumours | TERMINATED | NCT03746431 |
| Olaparib | DRUG | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06909825 |
| FPI-2265 | DRUG | Phase PHASE2 | Metastatic Castration Resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05219500 |
| ION269 | DRUG | Phase PHASE1 | Alzheimer Disease | TERMINATED | NCT06673069 |
| Sham procedure | PROCEDURE | Phase PHASE1 | Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome | RECRUITING | NCT06430385 |
| ION440 | DRUG | Phase PHASE1 | Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome | RECRUITING | NCT06430385 |
| ION717 | DRUG | Phase PHASE1 | Prion Disease | RECRUITING | NCT06153966 |
| ION356 | DRUG | Phase PHASE1 | Pelizaeus-Merzbacher Disease | RECRUITING | NCT06150716 |
| Pelacarsen | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05337878 |
| ION582 | DRUG | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| ION547 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04934891 |
| ION224 | DRUG | Phase PHASE2 | Steatohepatitis, Nonalcoholic | COMPLETED | NCT04932512 |
| zilganersen | DRUG | Preclinical | Alexander Disease | AVAILABLE | NCT07487389 |
| ION363 | DRUG | Phase PHASE3 | Amyotrophic Lateral Sclerosis | ACTIVE_NOT_RECRUITING | NCT04768972 |
| ION904 | DRUG | Phase PHASE2 | Hypertension | COMPLETED | NCT05314439 |
| IONIS-AGT-LRx | DRUG | Phase PHASE2 | Chronic Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT04836182 |
| ION537 | DRUG | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT04659096 |
| Olezarsen | DRUG | Preclinical | Familial Chylomicronemia Syndrome | APPROVED_FOR_MARKETING | NCT06360237 |
| Normal Saline | DRUG | Phase PHASE2 | Covid19 | COMPLETED | NCT04549922 |
| ISIS 721744 | DRUG | Phase PHASE2 | Covid19 | COMPLETED | NCT04549922 |
| GHR-LRX | DRUG | Phase PHASE2 | Acromegaly | COMPLETED | NCT04522180 |
| ION-827359 | DRUG | Phase PHASE2 | Chronic Bronchitis | TERMINATED | NCT04441788 |
| ION251 | DRUG | Phase PHASE1 | Relapsed Multiple Myeloma | COMPLETED | NCT04398485 |
| Magnetic Resonance Imaging (MRI) | OTHER | Preclinical | Spinocerebellar Ataxia Type 2 | COMPLETED | NCT04288128 |
| Lumbar puncture | PROCEDURE | Preclinical | Spinocerebellar Ataxia Type 2 | COMPLETED | NCT04288128 |
| ION464 | DRUG | Phase PHASE1 | Multiple System Atrophy | RECRUITING | NCT04165486 |
| Eplontersen | DRUG | Phase PHASE3 | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | ENROLLING_BY_INVITATION | NCT05667493 |
| sapablursen | DRUG | Phase PHASE2 | Phlebotomy Dependent Polycythemia Vera | ACTIVE_NOT_RECRUITING | NCT05143957 |
| BIIB094 | DRUG | Phase PHASE1 | Parkinson's Disease | COMPLETED | NCT03976349 |
| Somatostatin Receptor Ligand (SRL) | DRUG | Phase PHASE2 | Acromegaly | COMPLETED | NCT03967249 |
| IONIS GHR-LRx | DRUG | Phase PHASE2 | Acromegaly | COMPLETED | NCT03967249 |
| IONIS-FB-LRx | DRUG | Phase PHASE2 | Primary IgA Nephropathy | COMPLETED | NCT04014335 |
| ION-682884 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03728634 |
| ISIS 757456 | DRUG | Phase PHASE2 | Hypertension | COMPLETED | NCT04083222 |
| IONIS-ENaCRx | DRUG | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT03647228 |
| IONIS FXI-LRx | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03582462 |
| IONIS-GHR-LRx | DRUG | Phase PHASE2 | Acromegaly | COMPLETED | NCT03548415 |
| AKCEA-ANGPTL3-LRX | DRUG | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | WITHDRAWN | NCT03455777 |
| Placebo (sterline saline 0.9%) | DRUG | Phase PHASE2 | Geographic Atrophy | WITHDRAWN | NCT03446144 |
| IONIS-FB-Lrx | DRUG | Phase PHASE2 | Geographic Atrophy | WITHDRAWN | NCT03446144 |
| ISIS 678354 | DRUG | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT03385239 |
| ISIS 703802 20 mg | DRUG | Phase PHASE2 | NAFLD | COMPLETED | NCT03371355 |
| ISIS 703802 80 mg | DRUG | Phase PHASE2 | NAFLD | COMPLETED | NCT03371355 |
| ISIS 703802 40 mg | DRUG | Phase PHASE2 | NAFLD | COMPLETED | NCT03371355 |
| AKCEA-ANGPTL3-LRx | DRUG | Phase PHASE2 | Familial Partial Lipodystrophy | COMPLETED | NCT03514420 |
| IONIS DGAT2Rx | DRUG | Phase PHASE2 | Hepatic Steatosis | COMPLETED | NCT03334214 |
| Donidalorsen | DRUG | Phase PHASE3 | Hereditary Angioedema (HAE) | RECRUITING | NCT07298447 |
| IONIS MAPTRx | DRUG | Phase PHASE1 | Mild Alzheimer's Disease | COMPLETED | NCT03186989 |
| IONIS TMPRSS6-Lrx | DRUG | Phase PHASE1 | Thalassemia | COMPLETED | NCT03165864 |
| IONIS-PKKRx (ISIS 546254) | DRUG | Phase PHASE2 | Chronic Migraine | COMPLETED | NCT03108469 |
| Ionis AGT-LRx | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03101878 |
| ISIS 681257 | DRUG | Phase PHASE1 | Renal Impairment | COMPLETED | NCT03506854 |
| IONIS-HBVRx | DRUG | Phase PHASE2 | Hepatitis B | COMPLETED | NCT02981602 |
| Moxifloxacin | DRUG | Phase PHASE1 | Abnormalities, Cardiovascular | COMPLETED | NCT02910635 |
| Placebo Comparator | DRUG | Phase PHASE1 | Elevated Triglycerides (TG) | COMPLETED | NCT02900027 |
| APOC-III-L-Rx | DRUG | Phase PHASE1 | Elevated Triglycerides (TG) | COMPLETED | NCT02900027 |
| ISIS-GCGRRx | DRUG | Phase PHASE2 | Type 2 Diabetes | COMPLETED | NCT02824003 |
| IONIS ANGPTL3-LRx | DRUG | Phase PHASE1 | Hypertriglyceridemia | COMPLETED | NCT02709850 |
| Isis 420915/GSK 299872 | DRUG | Phase PHASE2 | Amyloidosis | WITHDRAWN | NCT02627820 |
| Tofersen | DRUG | Phase PHASE3 | ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation | COMPLETED | NCT03070119 |
| ISIS-GCGRRx- Dose Level 2 | DRUG | Phase PHASE2 | Type 2 Diabetes | COMPLETED | NCT02583919 |
| ISIS-GCGRRx- Dose Level 1 | DRUG | Phase PHASE2 | Type 2 Diabetes | COMPLETED | NCT02583919 |
| ISIS 416858 | DRUG | Phase PHASE2 | End-stage Renal Disease (ESRD) | COMPLETED | NCT03358030 |
| volanesorsen | DRUG | Phase PHASE2 | Familial Partial Lipodystrophy | TERMINATED | NCT02527343 |
| ISIS 443139 120 mg | DRUG | Phase PHASE1 | Huntington's Disease | COMPLETED | NCT02519036 |
| ISIS 443139 90 mg | DRUG | Phase PHASE1 | Huntington's Disease | COMPLETED | NCT02519036 |
| ISIS 443139 60 mg | DRUG | Phase PHASE1 | Huntington's Disease | COMPLETED | NCT02519036 |
| ISIS 443139 30 mg | DRUG | Phase PHASE1 | Huntington's Disease | COMPLETED | NCT02519036 |
| ISIS 443139 10 mg | DRUG | Phase PHASE1 | Huntington's Disease | COMPLETED | NCT02519036 |
| ISIS-FGFR4RX | DRUG | Phase PHASE2 | Obesity | COMPLETED | NCT02476019 |
| Sterile Normal Saline (0.9% NaCl) | DRUG | Phase PHASE1 | Elevated Lipoprotein(a) | COMPLETED | NCT02414594 |
| IONIS-APO(a)-LRx | DRUG | Phase PHASE1 | Elevated Lipoprotein(a) | COMPLETED | NCT02414594 |
| IONIS-DMPKRx | DRUG | Phase PHASE1 | Myotonic Dystrophy Type 1 | COMPLETED | NCT02312011 |
| ISIS-GCCRRx | DRUG | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01968265 |
| Enoxaparin | DRUG | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT01713361 |
| ISIS-FXIRx Dose #3 | DRUG | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT01713361 |
| ISIS-FXIRx Dose #2 | DRUG | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT01713361 |
| IONIS-STAT3Rx | DRUG | Phase PHASE1 | Advanced Cancers | COMPLETED | NCT01563302 |
| Volanesorsen | DRUG | Phase PHASE1 | Abnormalities, Cardiovascular | COMPLETED | NCT02910635 |
| ISIS-APO(a)Rx | DRUG | Phase PHASE2 | Elevated Lipoprotein(a) | COMPLETED | NCT02160899 |
| daily OAD (metformin and/or sulfonylurea) | DRUG | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01918865 |
| ISIS-PTP1BRx | DRUG | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01918865 |
| ISIS-GCGRRx - Dose Level 2 | DRUG | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01885260 |
| ISIS-GCGRRx - Dose Level 1 | DRUG | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01885260 |
| AZD9150 | DRUG | Phase PHASE1 | Advanced Adult Hepatocellular Carcinoma | COMPLETED | NCT01839604 |
| Inotersen | DRUG | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloid Polyneuropathy | COMPLETED | NCT04136184 |
| ISIS CRP Rx | DRUG | Phase PHASE2 | Paroxysmal Atrial Fibrillation | COMPLETED | NCT01710852 |
| ISIS-APOCIIIRX | DRUG | Phase PHASE2 | Type 2 Diabetes | TERMINATED | NCT01647308 |
| ISIS apoC-III Rx | DRUG | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT01529424 |
| ISIS CRP Rx or Placebo | DRUG | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT01414101 |
| Mipomersen | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00794664 |
| Mipomersen sodium | DRUG | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00770146 |
| ISIS 325568 | DRUG | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT00519727 |
| Carboplatin | DRUG | Phase PHASE1 | Non-small Cell Lung Cancer | COMPLETED | NCT01234038 |
| Paclitaxel | DRUG | Phase PHASE1 | Non-small Cell Lung Cancer | COMPLETED | NCT01234038 |
| Docetaxel | DRUG | Phase PHASE1 | Castrate-Resistant Prostate Cancer | COMPLETED | NCT01234025 |
| Prednisone | DRUG | Phase PHASE1 | Castrate-Resistant Prostate Cancer | COMPLETED | NCT01234025 |
| ISIS EIF4E Rx | DRUG | Phase PHASE1 | Non-small Cell Lung Cancer | COMPLETED | NCT01234038 |
| mipomersen sodium; warfarin sodium | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT01133366 |
| warfarin sodium | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT01133366 |
| moxifloxacin hydrochloride (Avelox®) | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT01090661 |
| ISIS 333611 | DRUG | Phase PHASE1 | Familial Amyotrophic Lateral Sclerosis | COMPLETED | NCT01041222 |
| ISIS 388626 | DRUG | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT00836225 |
| ISIS 353512 | DRUG | Phase PHASE1 | Inflammatory Diseases | COMPLETED | NCT00734240 |
| placebo | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01299298 |
| Mipomersen Sodium | DRUG | Phase PHASE3 | Lipid Metabolism, Inborn Errors | COMPLETED | NCT00694109 |
| Placebo | DRUG | Phase PHASE3 | Angelman Syndrome | RECRUITING | NCT06914609 |
| mipomersen | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01414881 |
| mipomersen sodium | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT01090661 |
| ISIS 113715 | DRUG | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT00455598 |
| ISIS 301012 | DRUG | Phase PHASE2 | Hypercholesterolemia, Familial | COMPLETED | NCT00280995 |
| ISIS 301012 or Placebo | DRUG | Phase PHASE2 | Hypercholesterolemia, Familial | COMPLETED | NCT00281008 |
| ISIS 14803, peginterferon alfa, ribavirin | DRUG | Phase PHASE1 | Hepatitis C, Chronic | COMPLETED | NCT00062816 |
| ISIS 104838 | DRUG | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00048321 |
| Alicaforsen | DRUG | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT00063830 |
| ISIS 14803 | DRUG | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT00035945 |
| paclitaxel | DRUG | Phase PHASE3 | Lung Cancer | COMPLETED | NCT00017407 |
| carboplatin | DRUG | Phase PHASE3 | Lung Cancer | COMPLETED | NCT00017407 |
| ISIS 3521 | BIOLOGICAL | Phase PHASE3 | Lung Cancer | COMPLETED | NCT00017407 |
| ISIS 2503 | DRUG | Phase PHASE2 | Pancreatic Cancer | COMPLETED | NCT00005594 |
| Ganciclovir | DRUG | Phase PHASE2 | Cytomegalovirus Retinitis | COMPLETED | NCT00002156 |
| Fomivirsen sodium | DRUG | Phase PHASE2 | Cytomegalovirus Retinitis | COMPLETED | NCT00002356 |
Total products: 885